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ABSTRACT 
 
 
 
Background: Magnesium has been implicated in the pathogenesis of 
acute myocardial infarction and its complication like arrhythmia. 
Magnesium improves myocardial metabolism, inhibits calcium 
accumulation and myocardial cell death. It improves vascular tone, 
peripheral vascular resistance, after load and cardiac output, reduces 
cardiac arrhythmias and improves lipid metabolism. Magnesium also 
reduces vulnerability to oxygen derived free radicals, improves 
endothelial function and inhibits platelet function including platelet 
aggregation and adhesion. 
 
Objective: To know the relationship between the serum magnesium 
levels and arrhythmias in patients with acute myocardial infarction. 
 
Method: By using simple random method, 50 cases of acute myocardial 
infarction, admitted in Coimbatore Medical College and Hospital. 
 
Results: There is a significant difference in the magnesium levels in 
patients with arrhythmias and without arrhythmias. 
 
Conclusion: In acute myocardial infarction, patients with low 
magnesium levels are more prone to get arrhythmias. So magnesium 
treatment can be considered in patients of acute myocardial infarction 
with low magnesium levels. 
 
Key words:  Magnesium; Myocardial infarction; Arrhythmias. 
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INTRODUCTION 
 
 
It has been known that inorganic salts are necessary for the 
normal growth and functioning of all biological forms. Pasteur 
(1860) proposed that yeast will grow only when inorganic 
compounds were present in the culture medium. In the human 
body, there is a maintenance of fluid balance, not only as a whole 
but also intercompartmentally between the three compartments 
such as intracellular, interstitial and intravascular fluid 
compartments. Various forces such as hemodynamic, electrolyte 
and other forces act together and contribute to maintain the normal 
fluid balance of the body. It is now evident that not only proteins, 
fats and carbohydrates, but also minerals play an essential role in 
the normal homeostasis of the body. Intensive investigation is now 
going on about the importance of trace elements not only of 
vitamins but also of minerals. 
 
Magnesium has been known to have an influence in the 
causation of acute myocardial infarction and also its sequelae like 
arrhythmias. It plays a major role in the pathogenesis of other 
cardiovascular diseases as well. Magnesium ions are found to be 
essential for the maintenance of the normal functional integrity of 
the myocardium
1
. 
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Several investigations have shown that the serum 
magnesium level  is low in the first 48 hours following a acute 
myocardial infarction and later on rose gradually to attain the 
normal level in about three weeks time. Infarcted  myocardium was 
found to have reduced  magnesium concentration. The above said  
findings correlated directly with the associated complications of 
acute myocardial infarction, such as arrhythmias. 
 
In patients with sudden death because of ischemic heart 
disease, magnesium concentration in the cardiac muscle was found 
to be decreased
2
.  Hypomagnesium  acts a provoking factor in the 
occurrence of ventricular fibrillation, which is usually the cause of 
sudden death in IHD. The coronary vasospasm which occurs as a 
result of hypomagnesemia has been considered as an important 
factor in the causation of sudden death in IHD. 
 
Magnesium deficiency contributes to the progression of 
atheromatous plaques occuring as a result of  hyperlipidemia. 
 
 Myocardial  infarction is one of the common causes of death 
where its prognosis depends on various factors. This study is 
designed to know the contribution of magnesium levels in the 
serum of acute MI patients to the occurrence of arrhythmias. 
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AIMS AND OBJECTIVES 
 
 
 
 
To know the correlation between serum magnesium levels 
and arrhythmias in patients with acute myocardial infarction who 
are presenting within 12 hours of onset of symptoms.
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REVIEW OF LITERATURE 
 
 
 
Historical Review 
 
During the time of Lavoisier (1743-1794) only 26 elements 
were discovered. Followed shortly by the discovery of elements 
such as sodium, potassium, calcium and magnesium. It was only 
Liebig (1803-1873) who  appreciated  the significance of the 
minerals as normal constituents of plants and animal tissues. 
Eventhough the inorganic constituents of the body constitute  only 
small fraction of the total amount,  they should not be considered as 
insignificant.  As a matter of fact, they are found to play a pivotal 
role in the maintenance of the normal homeostasis of the body.  
 
Greenberg and associates in 1936 demonstrated myocardial 
degeneration associated with fibrosis and polyplastic infiltration in 
rats fed on diets low in magnesium since birth (Burch et al, 1977)
1
. 
From the sequence of structural abnormalities observed it was 
interpreted that interference with the enzymes dependent on 
magnesium which are involved in oxidative phosphorylation was 
responsible for the pathogenesis of the lesion observed. 
The term ‘magnesium’ derived its name  from the name of
ancient Gracian town of ‘Magnesia’(a district of Thessaly). Sir 
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Humphrey Davy in 1808, investigated the alkaline earth metal and 
proposed the white magnesia stone by its modern name 
‘magnesium’.  
Until the middle of twentieth century, magnesium 
metabolism had not been given much importance, though extensive 
literature about the  consequences of magnesium deficiency in the 
lower species was available. During  this period,  the progress of 
the work on magnesium metabolism in man was very slow because 
of the lack of uniformity and difficulty in  estimating  magnesium 
levels and also the magnesium status of the body. 
 
Now the availability of more accurate and uniform means of 
serum magnesium estimation in the laboratory has escalated the 
work on magnesium metabolism in man to greater heights. 
 Only 1% of total body magnesium is present in the extra-
cellular fluid and out of this, about 25% is present in the plasma, 
rest is seen in the red cells. About 50% of serum magnesium is 
found to be free, 32% remains bound to proteins and the rest 13% 
exists as magnesium phosphate, citrate and other unidentified 
complexes. 
 
Since the intravascular space contributes to only a fractional 
6 
 
portion of the body involved in the homeostasis of magnesium, it is 
clear that the estimation of serum magnesium levels alone does not 
always  indicate the actual total body magnesium stores. 
 
As a matter of fact, magnesium deficiency can occur when 
the intracellular magnesium content is normal and intracellular 
magnesium deficiency may occur without any decrease in serum 
magnesium levels (Vermon et al, 1978)
3
. 
 Nevertheless, compared to the complex studies on 
determination of the tissue levels, measurement of serum 
magnesium is the rapid, simple and most effective approach for the 
assessment of magnesium deficiency states. Measurement of the 
serum magnesium levels has been used widely for identifying 
various clinical syndromes that have responded well to the 
replacement therapy with magnesium salts. 
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CORONARY CIRCULATION
04
 
 
 
 
 
Anatomy of Coronary circulation 
Coronary arterial system supplies blood to the heart. It is 
comprised of the right coronary artery and the left coronary artery. 
The origin of right coronary artery is from the anterior aortic 
sinus. Soon after its origin, it courses between the right auricular 
appendage and the infundibular portion of the right ventricle. It  
traverses in the atrioventricular groove passing vertically 
downwards. Then the  artery turns posteriorly at the lower border 
of the heart and courses posteriorly. It gives off several branches to 
both atria and ventricles as it passes down the atrio ventricular 
groove. At the inferior border of the heart, the marginal branch 
traverses to the left along the right ventricle. The inferior 
interventricular branch arises on the diaphragmatic surface and 
courses  along the groove in between the ventrices to the cardiac 
apex. The terminal branches of right coronary artery anastomoses 
with the terminal arterioles of the left coronary artery at the lower 
aspect of left atrium. 
The left coronary artery soon after its origin divides into left 
anterior descending artery (LAD) and left circumflex artery (LCA). 
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The left anterior descending artery traverses the interventricular 
groove to anastomoses with the terminal branches of the inferior 
interventricular artery, which is a branch of right coronary artery, at 
the apex. The left circumflex artery gives branches to the posterior 
wall of the left ventricle and courses down to anastomose with the 
termination of the right coronary artery, below the coronary sinus.  
In  40% of the individuals it gives off a larger branch which runs 
over the posterior surface of the left atrium terminates in the 
auricular appendage of the right atrium at the sino-atrial node. 
 
ARTERIAL SYSTEM OF THE HEART 
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VENOUS DRAINAGE OF THE HEART 
 
 
 
 
 
 
 
 
Anastomoses of Coronary Arteries 
 
There  exists an anastomoses between the terminal portions 
of right and left coronary arteries in the atrrioventricular groove but 
these surface anastomoses are insignificant. There exists 
10 
 
intercoronary  anastomoses at the arteriolar level, between the 
inter-ventricular arteries. If the intraventricular arteries meet at the 
apex, maximum anastomoses may be provided. If the 
intraventricular arteries meet slightly away from the apex above or 
below, the potential anastomotic area may be diminished. In 10% 
of the individuals, both the inferior as well as the anterior 
interventricular artery arises out of the left coronary artery itself, in 
these cases there is no anastomoses exists in this condition between 
the coronaries.  
There exists a potential anastomoses  between the coronary 
arteries and pericardial arteries which usually arises from the 
pericardiophrenic, the bronchial and the internal thoracic arteries. 
Very  rarely, one of these may open up to replace a coronary artery 
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CORONARY ANASTOMOSES 
 
 
Distribution of the Coronaries 
 
Right ventricle is supplied by the right coronary artery with 
the exception of the upper margin of its anterior surface which is 
supplied by branches of anterior interventricular arteries. 
12 
 
 
Left ventricle is supplied by the left coronary artery with the 
exception of a narrow strip of the diaphragmatic surface which is 
supplied by the inferior interventricular artery. The two 
interventricular arteries equally supplies the interventricular 
septum. 
 
Right  coronary artery supplies the anterior surface of the 
right atrium.  Left  coronary artery supplies the posterior surface 
and the auricular appendage of the left atrium. 
 
SA Node:  In 60% of cases, it is supplied by a branch of right 
coronary artery and in 40% of cases, it is from left coronary artery. 
The  inferior interventricular artery supplies AV node and bundle 
of His, which arises in 90% of cases from the right coronary artery 
and in only 10% from the left coronary artery. 
 
Dominant Arteries: Right coronary is dominant in 67% of the 
cases, in 15% of cases, left coronary artery is dominant and in 18% 
of cases, there is a balanced between these two. 
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CARDIAC PHYSIOLOGY 
 
Cardiac action potential 
 
 
 
 
 
 
 
 
Physiology of Coronary Circulation 
 
Physiologically, the right and left coronary arteries behave 
like end arteries, eventhough innumerable inter coronary 
anastomoses are present in most of the normal hearts. 
 
Normal Coronary Blood Flow 
14 
 
 
Coronary  blood flow in human beings during resting state is 
approximately about 225 ml/ min or 0.7-0.8 ml/g of cardiac muscle 
or 4.5% of the total cardiac output. This may increase upto 4 to 5 
fold during exercise. 
 
Coronary Blood Flow changes during cardiac cycle 
 
Because of cardiac muscle contraction, blood flow to the 
heart is decreased during systole and increased during diastole. 
Blood supply to the left ventricle is affected more than that of the 
right ventricle because of its increased thickness. 
 
During cardiac muscle contraction, the subendocardial blood 
vessels are compressed more than the epicardial vessels because of 
increased myocardial pressures. The  subendocardial vessels are 
usually larger compared to the nutrient arteries in the middle and 
external layers of the heart, which may cause a proportionate 
increase in the blood flow during cardiac diastole. Hence, 
subendocardial portions of the heart receive most of its blood 
supply during diastole. 
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Regulation  of Coronary Blood Flow: 
 
 Coronary blood flow can be regulated as follows: 
 
1. Local myocardial metabolism  
 
2. Nervous control  
 
 
i) Local metabolism of myocardium: As the force of 
contraction increases, the rate of coronary blood flow also 
increases. As the activity decreases, coronary blood flow 
also decreases. This is dependent on the following factors:  
 
a)  Oxygen Demand: 
As oxygen extraction is near complete in resting state only, 
increase in oxygen demand has to be met with by increasing the 
blood flow. This is achieved probably by the following 
mechanisms: 
 
1. Vasodilator Theory: Anoxia will liberate many vasodilator 
materials from myocardial cells which increase the blood flow: 
i) Adenosine from the ATP  
 
ii) Potassium ion  
 
iii) Hydrogen ion  
 
iv) Carbon dioxide  
 
v) Bradykinin and possibly  
 
vi) Prostaglandins  
16 
 
 
 
2. Arterial Smooth Muscle Relaxation Theory: Decrease in 
oxygen supply leads to anoxia of coronary arterial smooth 
muscle cells, which loses their tone thus getting the artery 
dilated. Factors that determine the oxygen consumption are:  
a) Greater the work, the greater the oxygen consumption, 
within the physiological limitations.  
b) Oxygen consumption is proportionate to peak myocardial 
muscle tension.  
 
i. Increased arterial pressure, increases the work load and 
hence tension.  
ii. Dilatation of the heart increases the tension development in 
myocardium to pump the blood according to Laplace law, 
which states that  tension  required  to  generate  a  given  
pressure  increases  in proportion to the diameter of the heart. 
 
c) Other factors which increases the oxygen consumption like 
stimulation of the heart by epinephrine and norepinephrine, 
thyroxine, digitalis, calcium ions, increased temperature of 
heart, will increase the oxygen consumption.  
d) Reactive hyperemia: Anoxia brings about increase flow 
17 
 
because of coronary dilatation after a brief period of 
coronary occlusion.  
 
iii) Nervous Control  
 
a) Indirect: Sympathetics increases the heart rate and 
contractility, through the local metabolic mechanisms, and 
hence increases the coronary flow. Parasympathetics 
decrease the heart rate and depresses the myocardium and 
hence brings about coronary constriction. 
b) Direct Effect: 
Parasympathetics: As the vagal supply to ventricles is 
negligible, except for slight dilatation which may occur, 
there is no effect of its stimulation. 
 
Sympathomimetics: Epinephrine and norepinephrine 
through their receptors in coronary vessels usually bring 
about vasoconstriction or no change. When alpha effect 
dominates, severe constriction occurs which may bring about 
anginal attack. 
18 
 
EPIDEMIOLOGY OF CORONARY HEART DISEASE
85
 
 
 
Coronary Artery Disease (CAD) is the major cause of 
morbidity and mortality in the age group of 45 years or more all 
over the world including India. Wide variations have been seen in 
the prevalence rate of CAD in various  geographical zones. Death 
rates from CAD seems to be higher in Finland and US. 
 
In the US, among those over 30 years of age it has been 
estimated that 213 per 100,000 individuals are said to have 
ischaemic heart disease. 
 
Accurate data about the prevalence of CAD in India are not 
available. Various surveys are carried out in recent years, in 
various  geographical locations and in small population groups 
which use different protocols. It has been estimated that the 
prevalence rate may be  about 5% in urban population and a much 
lower prevalence has been seen in the rural setting. 
The pattern of CAD in India has been reported to be: 
a) Males are affected more than females.  
b) Hypertension and diabetes accounts for about 40% of all 
cases.  
c) Heavy smoking is the precipitating factor in a large number 
19 
 
of cases.  
d) High fat & energy rich diet, sedentary life style are other 
contributing factors. 
It has been believed that the prevalence of CAD in India has 
been increasing over the last three decades and the younger persons 
are prone to the prone to develop CAD since 1970 because of the 
increasing risk factors. There has been approximately 30% 
reduction in mortality due to CAD. 
MYOCARDIAL INFARCTION 
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PATHOPHYSIOLOGY OF ACUTE MYOCARDIAL 
INFARCTION
85
 
Myocardial infarction occurs when there is an abrupt 
reduction in coronary blood flow usually occurring as a result of 
thrombotic occlusion of the  coronary artery already been narrowed 
by the formation of atherosclerotic plaques which fissures, ruptures 
or ulcerates and under favourable conditions  thrombogenesis may 
take place. A  mural thrombus forms at the site of plaque  rupture 
and leads to coronary artery occlusion. An initial platelet 
monolayer forms at the site of the plaque rupture, a series of 
agonists (collagen, ADP, epinephrine, serotonin)released may 
promote platelet activation. Following stimulation by agonists, 
thromboxane A2 is produced and released. This may further 
activate platelets and hence aggravating thrombogenesis. 
 
In addition to the production of thromboxane A2, platelet 
activation  by agonists produce a definitive conformational change 
in the glycoprotein IIb- IIIa receptors. Once it is converted to its 
functional state, glycoprotein IIb- IIIa receptor  develops a high 
affinity for the arginine – glycine – aspartic acid sequence on the 
alpha chain of the fibrinogen and also for a dodecapeptide 
sequence on the gamma chain of the fibrinogen. Fibrinogen  is a 
21 
 
multivalent molecule and  it has the ability to bind to two different 
platelets simultaneously, leading to  cross linking of platelets and 
aggregation. 
 
At the site of the plaque rupture, tissue factor is released 
from the damaged endothelial cells, which on exposure gets 
activated, followed by the activation of coagulation cascade occurs. 
Through extrinsic and intrinsic pathways, Factor VII and X are 
activated, ultimately leading to the conversion of prothrombin to 
thrombin, Thrombin, then converts fibrinogen to fibrin. Finally, 
crosslinkage of fibrin and formation of fibrin clot occurs. The  
coronary artery eventually gets occluded by a thrombus made up of 
platelet aggregates and fibrin strands. 
 
Ultimately the extent of myocardial damage produced by 
coronary occlusion depends upon the blood vessel affected, the 
territory it supplied, whether or not the vessel becomes totally 
occluded, presence of native factors which can produce early 
spontaneous lysis of the occlusive thrombus, the extent of collateral 
vasculature formation  and the  oxygen demand of the myocardium 
whose blood supply has been abruptly limited. 
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Chart 2 : ACLS 2010 GUIDELINES FOR THE 
MANAGEMENT OF ACUTE CORONARY SYNDROMES 
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CLINICAL FEATURES OF ACUTE MYOCARDIAL 
INFARCTION
85
 
 
Acute myocardial infarction usually presents itself as a 
sudden catastrophic accident and its clinical picture may be 
variable and unpredictable.  
AMI may present with one or combination of the following: 
1. Chest  pain  
2. Shock   
3. Pulmonary  edema or other evidence of LV failure.  
4. Congestive cardiac failure 
5. Some cases may present with combination of any of the 
above.  
1. Pain in the Chest: 
 
In 80-85% of cases this is the most common presenting 
complaint, characterized by a deep visceral pain usually involving 
the central portion of the chest and epigastrium, felt as tightness, 
heaviness or constriction in the chest. In 25% of cases, radiation of 
pain to the arms especially left arm and ulnar aspect of the forearm. 
It is commonly associated with weakness, forehead sweating, 
nausea, giddiness and anxiety. It may be precipitated by exertion 
25 
 
and emotional outbursts and not relieved with rest and compels the 
patient to move about to find a comfortable position. 
2. Breathlessness 
The next common symptom is breathlessness which may be 
sudden in onset, usually grade 2 or 3, may be exertional. It is 
usually seen in diabetics, elderly and those having complications 
like cardiogenic shock and pulmonary edema in whom it presents 
as ‘ silent myocardial infarction’.  
3. Sudden loss of consciousness, a sense of profound weakness or 
unexplained hypotension associated with giddiness, syncope,  
confusional state and/ or convulsions may be the presenting 
complaint.  
 
4. Choking sensation felt in the neck may be the only presenting 
symptom.  
 
Very few patients present with breathlessness of gradual 
onset, paroxysmal nocturnal dyspnea, abdominal pain with 
oliguria and bilateral pitting pedal edema, swelling of lower 
limbs, a picture characteristic of CCF.  
 
In rare cases, endocardial thrombosis may occur where the 
infarct may go unrecognized resulting in systemic embolism.  
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Physical Signs : Patient may arrive at the emergency room with 
the hand placed over their precordium where there is maximum 
intensity of pain (Levine sign). 
  
This may often be associated with perspiration and coolness 
of extremities, cyanosis may occur when the patient has severe 
pulmonary edema or shock. 
Pulse 
 
Bradycardia, normal sinus rhythm, tachycardia with or 
without irregularities, depends upon the presence or absence of 
arrhythmias and the type of arrhythmia. 
Blood Pressure 
 
Usually there may be an increase in BP initially because of 
pain, anxiety or the unfamiliarity of the environment, which 
becomes normal within 3 or 4 days. Decrease  in the blood pressure 
may occur as a result of cardiogenic shock or due to ‘Bezold-
Jarisch reflex’, which may be caused by increase vagal tone that 
occurs in inferior wall infarction. 
Neck veins: 
 
Collapse of neck veins may be seen when patient is in 
shock, cannon waves can be seen in case of complete heart block. 
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Precordium: 
 
There is a difficulty in palpating the apical impulse. In 
certain patients with anterior wall infarction, an abnormal systolic 
pulsation may be observed in the periapical area during the first 
few days of illness, which usually resolves later, representing a 
transient, palpable systolic bulging of the infarcted ventricle. 
Muffling of heart sounds, atrial (S4), ventricular (S3) gallop sounds 
and paradoxical splitting of the 2
nd
 sound. A apical systolic murmur 
due to mitral regurgitation may be heard transiently secondary to 
papillary muscle dysfunction in case of acute infarction. If  the 
infarction is transmural, pericardial friction rub may be heard. 
Temperature fluctuaions in the range of 37 to 38ºC are 
common during the first 3 to 4 days due because of myocardial 
necrosis. 
Respiratory System:  
Tachypnea may be present and fine crepitations may be 
heard at the base initially, then all over the lung fields depending 
upon the amount of pulmonary congestion. 
 
Gastrointestinal System:  
 Tender hepatomegaly may be present if there is congestive 
cardiac failure. 
28 
 
Central Nervous System:  
Anxiety, restlessness, stupor, coma, focal neurological 
deficit may be present. When there is hypotension, fall in blood 
pressure and/ or thromboembolic phenomenon. 
 
 
INFERIOR WALL MI 
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MAGNESIUM HOMEOSTASIS 
 
 
Magnesium (Mg) is the fourth cation to be seen in 
abundance in the body. It is the second most intracellular cation 
seen abundantly, next to potassium
5
. In adults, the normal 
magnesium content of the body is about approximately 2000 milli 
equivalents (meq) or 24 grams or 1000 mmol. Magnesium has an 
uneven distribution, with highest concentration in tissues with the 
high metabolic activity such as brain, heart and kidney. 
Approximately 60% of the total body magnesium is present in the 
bone. Out of which, one third has been shown to be exchangeable. 
This fraction of exchangeable magnesium serves as a reservoir for 
the maintenance of normal extracellular magnesium concentration. 
 
Extracellular magnesium constitutes only about 1% of total 
body magnesium content. The remaining of the body magnesium is 
intracellular. The normal serum magnesium concentration is about 
1.8 – 2.9 mgs/dl
7
approximately
. 
On an average, 70-75% of  
magnesium in plasma can be ultra filtered. The non-filterable 
portion remains bound to plasma proteins, especially albumin.  
 
The  intracellular magnesium concentration in various 
tissues vary widely, but is of the order of 1-3 mmols/ l
8
. In general, 
the metabolic activity of the cell is proportionate to its magnesium 
30 
 
content. Decrease in magnesium concentration in the serum, 
usually implies magnesium deficiency. However, the serum 
magnesium level may not reflect intracellular magnesium. 
Intracellular magnesium depletion may be seen despite a normal 
serum magnesium concentration
9
. Estimation of intracellular 
magnesium concentration is not usually done because of the 
difficulty in performing tissue and cellular assays. Hence, 
determination of the serum magnesium concentration is the method 
widely used in clinical practice to identify magnesium deficiency. 
 
Myocardial Magnesium 
 
Normal  body content of magnesium  is about  21 to 28 gms  
or about 3 mg/kg of fat free tissue. 60% of which  is present in the 
bone.  Magnesium is concentrated in significant amounts in cardiac 
muscle which is about 17.4- 19.8 meq/l.   Magnesium 
concentration in ventricles are found to be higher than that  in the 
atria. No significant difference has been found between magnesium 
concentration in the right and left ventricles or inter-ventricular 
septum (Burch et al, 1977)
1
. Magnesium has been found to be 
involved in various mechanisms essential for the contraction of 
heart muscle such as ATP hydrolysis by myofibrils, sineresis and 
super-precipitation of actinomycin gels, and binding and release of 
calcium ions by sacrotubule systems.  It  also stimulates oxidative 
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phosphorylation in mitochondria of the cardiac muscle, and 
influences sodium potassium ATPase of heart membranes, and 
activates adenylyl cyclase and also phosphorylase kinase in the 
heart. Magnesium also influences  muscle tone and conducting 
system of the heart, though sensitivity to magnesium is lesser in 
myocardium compared to the nervous tissue (Wecker et al, 1968)
5
. 
 
Renal handling of Magnesium 
 
Kidneys play a significant role in the regulation of 
magnesium homeostasis. Each day, about 8 meq of magnesium is 
excreted into the urine. In  magnesium depleted states, there is avid 
retention of magnesium  by the kidneys and only negligible 
quantities  of magnesium is lost in the urine per 24 hours period. If 
the dietary magnesium intake is high or administered parenterally,  
the filtered load exceeds the normal plasma concentration resulting 
in rapid excretion of excess magnesium
10
. In humans, the renal 
handling of magnesium   is mainly a filtration – reabsorption 
process. The  proximal tubule and thick ascending limb of Henle 
are found to be the important sites of magnesium retention. 
 
In the proximal convoluted tubule, there is a passive 
reabsorption of about 20 to 30 % filtered magnesium. Magnesium  
reabsorption follows change in salt and water reabsorption. About  
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65% of filtered magnesium is reabsorbed in the thick ascending 
limb of Henle by an active transport process. 
 
Aldosterone promotes the renal excretion of magnesium, 
whereas parathormone inhibits its excretion. Parathyroid hormone 
regulates both calcium and magnesium excretion and metabolism. 
Parathormone  reaction is reduced by increase in  blood 
magnesium concentration and vice versa
5
. In patients with either 
primary hyperparathyrodism or hypoparathyrodism, the serum 
magnesium concentration was found to be normal indicating that 
PTH plays only a minimal role in the regulation of magnesium 
homeostasis
10
. 
Intestinal absorption of magnesium 
 
The intestinal absorption of magnesium is inversely 
proportional to the intake of magnesium
11
. The recommended 
minimum requirement per day is 300-500 mg. The estimated 
magnesium intake per day ranges from 150-350 mg/day. In 
general, about 30-50% of ingested magnesium is absorbed
12
. 
Groundnuts, cereals pulses and meat are rich in magnesium. 
 
Absorption of magnesium  takes place throughout the GIT,   
the ileum and jejunum are the sites of maximum absorption. 
Magnesium is most efficiently absorbed in the alkaline 
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environment of small intestine in chloride form
13
. The higher 
fractional absorption at low dietary magnesium intake is because of 
the existence of an unsuitable passive transport system for 
magnesium absorption in addition to the hormone controlled 
magnesium transport. 
 
 Hormone controlled intestinal magnesium transport 
constitutes the major transport mechanism of magnesium. Vitamin-
D and its breakdown products, 25 hydroxy  and 1,25 dihydroxy 
compounds enhance magnesium absorption by the intestine
14
. 
Bioavailability of magnesium may also contribute to intestinal 
absorption of magnesium. The presence of certain substances  such 
as free fatty acids, phytates, oxalates, phosphate and fiber in excess 
in the ingested food may impair absorption by binding to it 
5
. 
 
Intracellular Magnesium 
 
Magnesium is intracellularly compartmentalized and is 
bound to proteins and other negatively charged molecules. 
Magnesium is present in the nucleus, mitochondria and 
endoplasmic reticulum as well as cytoplasm in significant 
quantities
15
. 80% of magnesium in the cytoplasm is present as a 
complex with adenosine triphosphate (ATP)
00
. The free ionized 
magnesium (mg
2+
) concentration is about 0.1 mmol/l  to 1 mmol/l. 
It is about 0.55 to 5% of the total cellular magnesium. The 
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intracellular magnesium concentration  seems to be maintained 
relatively constant. 
 
Various studies about magnesium transport have suggested 
that the rate at which magnesium exchange occurs in organs such 
as heart, liver and kidneys far exceeds that in the skeletal muscle, 
red cells and brain. There is an increase in intracellular magnesium 
content in rapidly proliferating normal cells indicating a possible 
relationship between the metabolic activity of a cell and relative 
rates of transport of magnesium into and out of cells.  Magnesium 
absorbed  is excreted by the kidneys and  the amount excreted in 
the stool is less than 1.4% of amount given. 
 
The kidneys filter about 2.5gm of magnesium approximately 
per day and retains 95% in normal conditions, excreting 
approximately 100 mg/day of magnesium in the urine for 
maintaining homeostasis. In magnesium depleted states,   kidneys 
retain magnesium and hence its excretion can be reduced to less 
than 12 mg/ day. 
Aldosterone promotes the renal excretion of magnesium, 
whereas parathormone inhibits its excretion. Parathormone also 
regulates calcium and magnesium excretion and metabolism. An 
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increase in the serum magnesium concentration inhibits the action 
of parathormone and vice versa
5
. 
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PHYSIOLOGICAL ROLE OF MAGNESIUM 
 
 
 
Magnesium plays a principal role in various enzymatic 
processes in the body
5
. It is essential for the formation of various 
substrates and it has a direct role in the activation of enzymes such 
as phosphofructokinase, creatine kinase, adenylate cyclase and 
sodium-potassium ATPase involved in various metabolic 
processes. The effect of magnesium on certain metabolic processes 
such as oxidative phosphorylation, glycolysis, protein biosynthesis,  
nucleotide metabolism implies the significance of magnesium in 
cellular metabolism. 
 
Magnesium activates the sodium-potassium ATPase, thereby   
maintaining  low extracellular and high intracellular potassium 
levels against large concentration gradients. It has been shown that 
hypomagnesemia may cause  impairment  of the  ability of the cells 
to maintain the potassium gradient which may lead to intracellular 
potassium depletion. 
 
The compromise in the cell membrane cation pump results 
in loss of intracellular potassium  associated with the  accumulation 
of intracellular sodium. This is similar to the effect which occurs 
during therapy with digitalis and this is how hypomagnesemia 
37 
 
causes digitalis toxicity. 
Influence of Magnesium on the tone of the blood vessels 
 
Magnesium is known to be a naturally available calcium  
antagonist
41
. It decreases the output of calcium  out of and into the 
calcium stores,   and protecting the tissues against the excess 
amounts of cacium occurring during states of reduced blood supply 
to the heart. Magnesium decreases the resistance of both systemic 
and pulmonary blood vessels resulting in drop in blood pressure 
and an rise in cardiac index
42
. Increase in extracellular magnesium 
level decreases the arteriolar tone in various arteries
43
 and 
augments the vasodilatory action of certain substances occuring in 
vivo and also administered pharmacological (isoproterenol and 
nitroprusside) vasodilators
43
. Because of its mild reducing effect on 
systolic blood pressure, magnesium may reduce the resistance of 
the systemic vessels unloading the ischemic ventricles. Kugiyama 
et al
44
 showed that in patients with variant angina,  angina pectoris 
stimulated by exercise may abolished by administration  
magnesium parenterally, perhaps due to suppression of coronary 
artery spasm thereby improving  regional myocardial blood flow.  
Altura and Altura
45
 in an experimental  model using smooth musce 
of the blood vessels found that hypomagnesemia could be 
responsible for the increase in arterial pressure  occuring in toxic 
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states of pregnancy. This effect may be due to potentiation of 
increased intracellular calcium activity. The response to 
intravenous magnesium therapy eclampsia may be due to  its 
calcium inhibitory effect. 
Influence of magnesium on rhythm of the heart  
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Hypomagnesemia may be found usually alongwith  hypokalemia, 
sodium excess and increased excitation of the cells. Magnesium 
has the following  effects such as prolongation of the actual and 
corrected recovery time of the sinus node, prolongation of the 
function of the atrioventricular node, relative and effective periods 
of refractoriness, increase in the length of the QRS complex during 
pacing of the ventricle  and increase in the interval between  atrium 
and His bundle  resulting in atrioventricular nodal Wenckebach 
conduction
46
. In 1935, Zwillinger
31
 first  observed that magnesium 
has an inhibitory effect on the initiation of arrhythmias when it was 
used to convert paroxysmal tachycardia to sinus rhythm. 
Thereafter, it was successfully used in the treatment of  ventricular 
tachycardias not responding to treatment, ventricular arrhythmias 
caused by overdosage with digitalis , also in torsades de pointes,  
ventricular dysrhythmia which may be prove fatal. 
 
Magnesium  may be considered to be useful in the treatment 
of dysrhythmias of supraventricular origin, (e.g)  atrial tachycardia 
of multifocal origin. It also increases the responsiveness of 
tachycardia of atrial origin to the drug therapy with digoxin. 
 
According to ACC/AHA  guidelines, magnesium has been 
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considered as the drug therapy of third choice (amiodarone as the 
1
st
  choice and lidocaine as the 2
nd
 choice ) in the ACLS protocol 
for CPCR of patients with shockable peri arrest rhythms. 
 
 
Infuence of Magnesium on metabolism of lipids 
 
 Magnesium has an important role in regulating the 
metabolism of lipids eventhough its mechanism is not known  
completely.   Magnesium serves as an adjunct  of two enzymes that 
play an important role in the metabolism of lipids; lecithin-
cholesterol acyltransferase (LACT) and lipoprotein lipase. In an 
experimental study with rabbit model, animals were fed with a 
normal diet, or a diet rich in cholesterol plus supplemention of 
variable quantities of magnesium. The addition of supplemental 
magnesium has been found to achieve a dose-dependent drop in the 
cholesterol content in large vessels such as aorta
48  
  associated with 
reduction in aortic lesions. On the other hand, in rats which are fed 
with magnesium deficient diets, adverse lipid changes occured. In a 
rat model, diets completely  devoid of magnesium resulted in 
increase in the levels of total cholesterol, LDL-cholesterol and 
triglycerides in plasma, with a corresponding decrease in plasma 
levels of high density lipoproteins-cholesterol (HDL-C)
49
. 
 
Rassmussen et al
51
 administered magnesium 15 mmol/ day 
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for a period of 3 months and noticed that there was a 27% drop in  
triglycerides and (VLDL-C) levels in plasma associated with 
decrease in levels of apoprotein B and increase in HDL-C levels in 
plasma. 
 
Davis et al
50
 in their 4-month clinical trial reported a 
remarkable increase in the ratio of HDL-C , LDL-C and VLDL-C 
by the  administration of magnesium 18 mmol per day  
 
Niemela et al
52
 reported that in men, but not in women, the 
intracellular levels of magnesium in platelets are inversely 
proportional to th serum levels of total cholesterol , LDL-C  and 
apolipoprotein B in the serum. They also reported that decrease in  
intracellular levels of magnesium in platelets may cause alterations 
in the cell membrane of platelets. This, in turn  may influence the 
participation of platelets in thrombus and atheroma formation. 
Magnesium as an anticoagulant/ antiplatelet 
 
Greville and Lehmann
53
 in the year 1943, observed that 
addition of little quantity of magnesium to freshly prepared  human 
plasma which is unclotted I nature resulted in prolongation of the 
time taken for clotting .  In Germany, sulphate salt of magnesium  
has been used widely for skeletal muscle relaxation, and it has been 
noted after the examination of their blood postmortem that their 
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blood has not clotted after the administration of sulphate salt of 
magnesium.  Anstall et al
54
 in 1959 showed  that magnesium can 
inhibit coagulation of human blood. 
 
Many  studies have reported that magnesium by its effects as 
a platelet inhibiting agent can  reduce the progression of  thrombi 
in the coronary arteries and also complete block of the  coronary 
artery after  recanalization which has occurred either by itself 
orstimulated by the process of fibrinolysis
55,56
. Numerous  studies 
have analysed and reported the effect of magnesium in the 
inhibition of aggregation of platelets in  volunteers who aredevoid 
of the disease
55,56
. Elevated levels of magnesium  in plasma may 
suppress clotting of blood and initiation of thrombus  in  the body, 
decrease aggregation of platelets, decrease the production of  
thromboxane A2,  which acts as an agonist on platelets and suppress 
the inward current of  calcium, which may be stimulated by 
thrombin. 
 
Activation of  platelets  is the major step in involved in acute 
vascular thrombosis of the vasculature, which contributes to the 
causation of AMI and expected adverse effect after  coronary 
balloon angioplasty and stenting. Various studies have reported that 
magnesium can suppress the stimulation of platelets by suppressing 
the factors which stimulate platelets like thromboxane A2 or by 
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inducing the production of factors which inhibit platelets like 
prostacyclin
57,58
. IV infusion of magnesium in volunteers who were 
healthy, suppressed the  aggregation of platelets which was induced 
by ADP by about 40%.  The  attachment of fibrinogen or 
expression glycoprotein IIb-IIIa complex GMP-140 on the surface 
was also inhibited by about 30%
58
. Hence, magnesium at 
therapeutic concentrations, intensively suppresses the function of 
the platelets. 
 
Gawaz
59
 et al demonstrated that there was an increase in the 
surface expression of  P-selectin  on  the surface of platelets which 
may be expressed on its own or induced by ADP, also a rise  in the 
adhesion of platelet and leucocyte in  patients who were 
symptomatic with coronary artery disease compared to the controls 
who were healthy. However, there was a significant reduction in 
both expression of P-selectin on platelet surface and adhesion of 
platelet leukocyte  after administration of intravenous magnesium. 
 
 
Influence of magnesium on endothelial function: 
 
 
In an animal model, Pearson et al
60
 showed that magnesium 
deficiency caused  selective impairment of the discharge  of NO 
from  endothelium of the coronary vassculature. NO is a  
nitrovasodilator produced in vivo and it may suppress adhesion and 
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aggregation of platelets . Hence, it has been considered that 
magnesium deficiency may cause constriction of the vasculature  
and eventually thrombosis of the coronary arteries. 
 
Influence of Magnesium on the extent of infarction 
 
Magnesium deficiency can cause vasoconstriction  of the 
coronary and systemic vasculature and may increase systemic 
vascular resistance. Magnesium administration can suppress  the 
worsening of ischemia if started as early as possible during the 
initial stages of occurrence of ischaemia.  This, in turn can decrease 
the occurrence of arrhythmias due to  elevated levels of  
catecholamines.
61
 
 
In animal studies, it has been shown that low magnesium 
concentrations  may stimulate the causation of myocardial necrosis 
induced by catecholamines
61
. Hypomagnesemia can also affect the 
healing process, healing of the blood vessels and  infarcted tissues 
of the heart and can also cause  incomplete angiogenesis
62
. These 
changes can contribute to potentially lead to inadequacy in the 
formation of collateral circulation and extension of the infarct. 
Magnesium decreases the susceptibility of the myocardium to free 
radicals released due to superoxidation, injury due to reperfusion  
and  stunning of myocardium. 
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HYPOMAGNESEMIA 
 
 
 
 
Magnesium has been called occasionally the “forgotten 
cation”. The changing trends in the diagnosis of electrolyte 
disturbances has now brought the  cation  into the limelight. 
Hypomagnesemia  is now well recognized due to increased clinical 
awareness, and the greater frequency of assessment of magnesium 
status. Approximately 10% of the admissions at major health care 
facilities  are found to be hypomagnesemic. This may escalate to as 
much as 65%   in severely ill patients. Hypomagnesemia  
commonly occurs due to loss of magnesium  from either the 
gastrointestinal tract or the kidneys. 
ETIOLOGY: 
Due to decreased magnesium intake :  
• Dependence  on alcohol 
•  Parenteral administration of  nutrition  
• Starvation 
Due to redistribution of magnesium  
• Syndrome of refeeding 
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•  diabetic ketoacidosis- treatment 
• Acute pancreatitis 
• alcohol withdrawal  
• Hungry bone disease 
Gastrointestinal  magnesium loss : 
• Nasogastric suction   
• Diarrhea 
• Vomiting   
• Gastrointestinal fistulas  
• Secondary to hypocalcemia  
 Renal magnesium loss 
• Gitelman syndrome 
• Familial hypomagnesemia with hypercalciuria and 
nephrocalcinosis (FHHNC) 
• Classic Bartter syndrome (Type III Bartter syndrome) 
•  ADHH 
• IRH with normocalcemia 
• IDH with hypocalciuria 
• Hypomagnesemia secondary to hypocalcemia  
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Drugs : 
• Antimicrobials - Amphotericin B, aminoglycosides, 
pentamidine, capreomycin, viomycin, and foscarnet 
• Diuretics - Loop diuretics, osmotic diuretics, and thiazides  
on prolonged  use 
•  Cisplatin 
•  Tacrolimus and cyclosporine 
• Omeprazole, pantoprazole 
Other causes :
 
 
• Ethanol
 
 
• Hypercalcemia 
• Chronic metabolic acidosis 
• Primary hyperaldosteronism 
• Acute tubular necrosis – recovery phase 
Hypomagnesemia may be seen in about 28% of patients with 
acute hemorrhagic pancreatitis. The low serum magnesium 
concentration may predispose to pancreatitis. 
 
Renal wasting of magnesium 
 
Loss of magnesium in the urine is underlying mechanism of 
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hypomagnesemia in many patients. Reabsorption of magnesium 
from the proximal renal tubule is in parellel with the fluid flow 
through the renal tubule and retention of sodium
63
. Hence,  
intravenous fluid administration for prolonged period of time, 
especially with sodium containing fluid may result in 
hypomagnesemia. Similarly in diabetic mellitus, osmotic diuresis 
may result in loss of magnesium in the urine. 
Hypercalcemia has been known to reduce absorption of 
magnesium in the proximal tubule and loop of Henle and probably 
is the mechanism of renal magnesium loss or the tendency towards 
hypomagnesemia in most of the conditions of hypercalcemia 
64
. 
Gastrointestinal Disorder 
 
The magnesium level of gastrointestinal tract is about 1 
meq/l on an average. Hence, emesis and suctioning through 
nasogastric tube may contribute to magnesium loss. The 
magnesium lost through fistulous drainage and diarrheal fluid are 
very high (up to 15 meq/l) and hence, magnesium deficiency is 
much commonly seen in diarrheal diseases of acute or chronic 
origin , ulcerative colitis, Crohn’s disease,  fistulous lesions of the 
intestinal and biliary systems 
65
. 
 Syndromes of altered absorption occurring due to non-
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tropical disease, injury due to exposure to radiotherapy given in 
diseases like   carcinoma related to the head of the pancreas and 
cervical carcinoma can lead to magnesium depletion probably 
because of the damage to the mucosa of the intestines
66
. Fatty 
stools can cause formation of non-absorbable magnesium lipid salts 
resulting in magnesium malabsorption.  Small bowel surgeries used 
for the treatment of certain bowel disorders may also result in 
hypomagnesemia. 
 
The commonest cause of magnesium loss is liberal use of 
diuretics
67
. Diuretic drugs acting on the proximal renal tubules, 
such as mannitol and carbonic anhydrase inhibitors,can increase 
excretion of  magnesium. Diuretics such as frusemide and 
ethacrynic acid act at the thick ascending Henle’s loop may result 
in magnesium deficiency. 
 
Aminoglycoside therapy  using  capreomycin, gentamycin 
and recently with tobramycin, amikacin has been shown to produce 
renal magnesium wasting. Use of certain antifungal agents may 
also lead to magnesium loss through the kidneys. Cisplastin, a 
chemo-therapeutic drug used in the therapy for neoplasms of 
epithelial tissues  may lead to renal magnesium wasting . 
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Endocrine and Metabolic Disorders 
 
Some endocrine and metabolic diseases are also associated 
with magnesium loss, which commonly occurs through renal 
magnesium loss. Diabetes mellitus is the commonest disorder of 
metabolism found with hypomagnesemia
68
. The  magnesium levels 
in the serum is inversely proportional to the  glucose levels in the 
serum and also the extent of glycosuria. The process of magnesium 
wasting in diabetes mellitus may probably be due to glycosuria 
(osmotic diuresis)
69
. And also, insulin may cause  shifting of 
magnesium into the cell resulting in magnesium deficiency. 
 
Hypomagnesemia can also be seen in various other 
endocrine abnormalities. Hypophosphatemia  has been shown to 
produce loss of magnesium in urine resulting in hypomagnesemia.  
Hence, hypophosphatemia acts as a contributing factor in the 
causation of magnesium deficiency. 
 
Other conditions such as hyperthyroidism, thyrotoxicosis 
may also cause urinary magnesium wasting  resulting in 
hypomagnesemia. In primary hyperaldosteronism, 
hypomagnesemia may be due  to plasma volume expansion 
followed by renal magnesium wasting. 
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Miscellaneous Causes 
 
Magnesium  wasting fron the entire body can occur via 
uncommon modes of excretion. Abnormal  sweating may result in 
significant extent of magnesium losses. 
 
Pancreatitis may also cause magnesium deficiency but the  
basis of loss of magnesium seems to be  unknown. It has been 
postulated that abnormal deposition of magnesium and fat 
complexes in the soft tissues may be one of the causes. Magnesium  
redistribution  into intracellular compartment or  the bone is the 
most common reason for reduction in magnesium levels in the 
serum. 
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MAGNESIUM AND ACUTE MYOCARDIAL INFARCTION 
 
 Epidemiological studies have proposed that the incidence of 
myocardial infarction and of sudden death is high in areas of soft 
water intake
2
. Myocardial magnesium  content   has been found to 
be decreased in patients whose death was attributed to acute 
myocardial infarction
16
.  However, it is not known whether the 
decrease in magnesium content predisposes to myocardial 
infarction or is result of it. Myocardial magnesium gets exchanged  
rapidly with plasma magnesium.  A number of clinical trials have 
shown a drop  in the  concentration of magnesium in the serum  
within the first 24 to 48 hours after acute myocardial infarction
17
. 
Various studies have shown that there is a fall in magnesium 
concentration in the infarcted myocardium but  the serum 
magnesium values in first 24 hours, following acute myocardial 
infarction has been variable. Some studies showed no significant 
change of serum magnesium. Hence, it has been proposed that 
there exists a reverse relationship between serum magnesium level 
in the serum and  coagulability of the blood, serum cholesterol 
levels, following acute myocardial infarction. 
 
 
Injury to the  myocardium was confirmed by histological 
examination of cardiac tissue. A marked elevation in the loss of 
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magnesium in the urine was seen during the first two hours. The  
level decreased soon after that but was still maintained above the 
control level. In  the infarcted myocardium,  magnesium content 
decreased significantly. 
Various authors have demonstrated a reduction in serum 
magnesium level following AMI. Abraham S et al
17
 (1980)  studied 
serum magnesium levels in forty two patients with acute MI, nine 
patients with coronary insufficiency and fourteen patients with 
non-cardiac chest pain. In patients with acute MI and those with 
acute coronary insufficiency, a reduction of magnesium levels in 
the  serum compared was seen, whereas  no difference has been 
noted in patients with non-cardiac chest pain. A marked reduction 
of magnesium  levels in the serum was noted during the first five 
days and normal levels were recorded by the 12
th
 day. 
 
Singh A et al
75
 (1976) measured  magnesium levels in the 
serum of  twenty patients diagnosed of having acute MI on the first 
7
th
 and 12
th
 day of admission. Significant  reduction in serum 
magnesium level has been recorded in all the cases on the first day. 
 
Babel S.Bhatnagar, HNS Bhatnagar
18
 (1983) studied the 
prognostic significance of serum magnesium levels in patients with 
acute MI. Twenty five patients diagnosed to have acute MI were 
taken as the study population. Serum levels were reported to be 
54 
 
significantly reduced on the first day and it gradually increased and 
attained the normal value by the twenty first day. 
 
Certain  studies have reported that magnesium deficiency 
resulted in decrease in intracellular magnesium and potassium and 
increase in intracellular calcium and sodium
19
. In  patients with 
coronary artery disease there was a decrease in the  exchangeable 
magnesium and  in patients diagnosed of having acute myocardial 
infarction, there was retention of  abnormally high quantities  of 
magnesium during magnesium tolerance test. Skeletal muscle 
magnesium content was found to be reduced, suggesting the 
presence of hypomagnesemia
20
. 
 
Magnesium deficiency predisposes to vascular spasms 
especially coronary artery spasm and also potentiates the 
contractile response to vasopressors such as angiotensin II and 
norepinephrine. Magnesium deficiency  may worsen angina and 
may predispose to acute myocardial infarction.  Magnesium  
therapy in acute MI has been shown to reduce infarction size,  the 
incidence of cardiac arrhythmias and also the mortality rate
21,22,23
. 
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ANTEROSEPTAL MI 
Chart 1 : ACC/AHA GUIDELINES FOR THE 
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
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MAGNESIUM AND ARRHYTHMIAS 
 
 
 
CLASSIFICATION OF TACHYARRYTHMIAS 
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Mechanism of Tachyarrhythmias: 
 
The mechanism by which magnesium decreases the 
incidence of cardiac dysrrhythmias remains unknown. Magnesium 
is essential for ATP activation, which is necessary for the 
maintenance of the sodium-potassium pump.  It has a significant 
role in the  maintenance of the resting membrane potential of 
electrocardiac cells, which is dependent on the intracellular 
potassium gradient. Magnesium deficiency may be  associated with 
decrease in  intracellular potassium, an increase in intracellular 
sodium concentration and an increase in excitability of the cardiac 
cells. It has been hypothesized that  absence of reentry of 
potassium into the depolarized cell or a  loss of potassium from 
already depolarized cells may result in abnormal conduction, 
phenomena of reentry and  fibrillation 
26,27  
of the ventricles. 
 
 
Another theory proposes magnesium to be a calcium   
blocker. The increase in intracellular sodium occurring due to 
magnesium depletion may be followed by a sodium-calcium 
exchange, resulting in an increase in intracellular calcium. Phasic 
influx of intracellular calcium may predispose to transient 
depolarization leading to repetitive dysrhythmias.  Infusion  of 
58 
 
magnesium has been shown to produce a clinical scenario similar 
to that produced by the infusion of a calcium channel blocking 
agent, characterized by peripheral vasodilatation, flushing, 
hypotension and  decreased contractile strength of the heart
28
. 
 
Lysophosphatidyl choline (LPC) is an endogenous 
phospholipid usually released from the cell membranes during 
periods of ischemia and has significant local effects on cardiac 
tissue. LPC promotes membrane depolarization by reducing 
potassium conductance of the inward rectified current, thereby 
inducing cardiac arrhythmias. LPC also induces intracellular 
calcium accumulation in cardiac cells by the inhibition of  sodium-
potassium adenosine triphosphatase (ATPase) pump
29
. Increase in  
cytosolic calcium may prove detrimental to the cells by subsequent 
activation of calcium dependent phospholipases and proteases and 
by the  generation of additional toxic fatty acids. Excess free 
intracellular calcium may potentiate the harmful effects of free 
radicals
30
.  Magnesium  serves as a critical cofactor of numerous 
myocardial ion pumps and also antagonizes calcium influx. 
Magnesium inhibits LPC induced increase in intracellular calcium. 
Hence, producing its  antiarrhythmic effects  by this mechanism. 
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Ventricular Tachyarrhythmias and Magnesium 
 Zwillinger
31  
in 1935,  administered 15 ml bolus of a 20% 
solution of magnesium sulfate (MgSO4)  into the left ventricle of a 
patient with refractory ventricular fibrillation resistant to other 
therapy. It has been noted that the rhythm changed  immediately to 
sinus rhythm. 
 
 
 
 
 
 
 
Boyd and Schesf
32
 in 1943 used 10-20 ml of 10% MgSO4 for 
treating spontaneous dysrrhythmias.. 
 
Rasmussen et al
33 
 administered about  1.2 g of magnesium 
chloride (MgCl2) to the patients with acute MI in the first 24 hours 
after AMI and about 300 mg in the second 24 hours.  After 
comparing the results with placebo control group, it was concluded 
that  those patients treated with MgCl2 had significantly lesser 
incidence of dysrrhythmias (21% in control group   versus 47%in 
study group) (p<0.05). 
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Digitalis  toxicity induced ventricular dysrrhythmias  are 
highly responsive to magnesium therapy. Magnesium deficiency is 
often seen  during digitalis toxicity. Eventhough  the serum 
magnesium levels are found to be normal, the intracellular 
magnesium is often decreased. Magnesium is antagonistic to the 
inhibitory effects of digitalis on sodium/ potassium ATPase. 
During therapy with digitalis, increase in intracellular calcium 
occurs resulting in increase in cellular excitability and inotropism 
34
. In a study in monkeys, low magnesium levels were found to 
increase the risk and duration of digitalis toxicity. 
VPCs 
 
 
 
Holden et al
35
 observed a marked reduction in Mg
2+
 during 
cardiovascular bypass surgery and also the first postoperative day. 
Dysrhythmias  following cardiovascular surgery are reported to be 
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partially caused by hypomagnesemia occuring as a result of  
anticoagulants usage during surgery. Anticoagulants causes 
hypomagnesemia by binding with Mg
2+
.  Administration  of Mg
++
 
during the postoperative period has reduced the incidence of 
dysrrhythmias. 
 
Torsades de Pointes 
 
Torsades de Pointes (TdP) is a life-threatening ventricular 
dysrhythmia characterised repetitive polymorphic ventricular 
tachycardia commonly occurs in conditions where QT prolongation 
is seen.  TdP is  induced by type Ia antidysrhythmic drugs such as 
quinidine or disopyramide.  Amiodarone,   which produces QT 
prolongation may cause TdP. Hypokalemia and hypomagnesemia 
may also induce  the occurance of TdP and in rare cases can be the 
cause
36
.  
 
In a longitudinal study of 12 patients with TdP , a single 
bolus dose of 2g of MgSO4 reverted TdP within 1 to 5 minutes in 
nine patients
27
. In the other three patients, a second dose of MgSO4 
given  after 5 to 15 minutes   TdP completely. No side effects were 
associated with the treatment.    
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Chart 3: ACC/AHA 2010 GUIDELINES FOR THE 
MANAGEMENT OF ADUT TACHYCARDIA 
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Atrial dysrrhythmias 
 
Treatment  of  atrial fibrillation (AF) becomes difficult
38  
in 
patients with magnesium deficiency. In a study of 45  patients with 
atrial fibrillation, 20% had serum magnesium levels approximately  
<1.5 mEq/L.  Magnesium         deficient  patients needed twice the 
dose of IV digoxin to control AF. From the  study it has been 
inferred that monitoring of serum magnesium level and magnesium 
replacement  may prove to be useful  in patients with symptomatic 
AF, especially in patients on digoxin therapy 
39
.  
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CLINICAL MANIFESTATIONS OF HYPOMAGNESEMIA  
 
 
 
 
Intake of diets poor in magnesium in otherwise normal 
persons may lead  to a syndrome characterized clinically by 
features like personality change, tremor, fasciculation ,  generalized 
spasticity and spontaneous carpo-pedal spasm. Administration of 
dietary magnesium results in a complete remission of its 
manifestations. 
 
As magnesium deficiency usually occurs alongwith a 
primary  pathology or  a therapy. The  effects of magnesium 
deficiency may be masked by the manifestations of the major 
illness.  Hypomagnesemia either moderate or severe can manifest 
as follows: 
 
Table-1 
 
Manifestations of Moderate to Severe hypomagnesemia 
 
Biochemical 
 
 Hypocalcemia  
 
• Impaired PTH secretion  
 
• Renal and skeletal resistance to PTH  
 
• Resistance to vitamin D.  
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Hypokalemia
8
 
 
• Renal potassium wasting  
• Decreased intracellular potassium 
 
Neuromuscular 
 
• Seizures 
• carpo-pedal spasms  
• Muscular weakness, loss of musce bulk 
• Nystagmus,  vertigo, ataxia,.  
• Psychiatric: Depressive and psychotic illness 
• Athetoid  movements 
•  choreiform movements  
 
Cardiac Arrhythmias 
 
ECG – prolongation of PR , QT interval and appearance of U-
waves 
Atrial tachycardia, atrial premature beats, atrial fibrillation 
Ventricular premature beats 
Ventricular tachycardia and fibrillation 
Torsades de pointes (TdP) 
Myocardial infarction  
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Biochemical Abnormalities 
 
Hypokalemia 
 
Hypokalemia is the most common feature of 
hypomagnesemia. During magnesium depletion, there is a loss of 
intracellular potassium resulting in  subsequent  depletion of 
intracellular potassium. This is followed by the failure of the  
kidney to retain potassium. Replacement  of  the potassium deficit 
with potassium therapy without simultaneous magnesium therapy 
may prove unsuccessful. The reason for the deranged metabolism 
of potassium may be due to dependence of Mg
2+
 on the Na
+
 K
+
 
ATPase. During magnesium depletion , there is an increase in 
intracellular sodium and calcium associated with decrease in 
magnesium and potassium. 
 
Magnesium seems to play a significant role in the regulation 
of potassium channels in cardiac cells. 
 
Hypocalcemia 
 
Hypomagnesemia is one of the most common causes of 
hypocalcemia
70
. In patients with hypocalcemia associated with 
hypomagnesemia, serum concentration of parathormone may be  
usually reduced. 
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Patients with hypomagnesemia are also resistant to the 
effects of vitamin-D. This has been attributed  to the  impairment in 
the metabolism of vitamin-D because of reduced concentration of 
1, 25 dihydroxy vitamin-D  in the serum. Hence, it should be taken 
into account that calcium or vitamin D therapy for the 
hypomagnesemia induced hypocalcemia may not be usually 
sufficient to correct  hypocalemia. Magnesium therapy is indicated 
for regaining  normal serum calcium concentration. 
 
Neuromuscular effects 
 
Neuromuscular hyper-excitability is the most common 
presenting complaint in a patient with hypomagnesemia. Latent 
tetany, characterized by positive Chvostek’s and Trousseau’s sign, 
or occurance of spontaneous carpo-pedal spasm may be found. 
Generalized tonic- clonic seizures may also occur. 
 
Other signs often seen include vertigo, ataxia, nystagmus, 
athetoid and choreiform movements, tremor, muscular 
fasciculation,muscle wasting and weakness also may be seen
5
. 
 
The various mechanisms involved in neuromuscular 
manifestations include the following: 
i) Magnesium is necessary for the stabilization of the nerve 
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axon. Decrease in the serum magnesium concentration 
reduces the  threshold for  stimulation of the axon and 
increases the velocity of nerve conduction.  
ii) Magnesium induces the release of neuro-transmitters at the 
neuromuscular junction by inhibiting competitively, the 
entry of calcium into the pre-synaptic nerve terminal
71
. A 
fall in extracellular Mg
2+
 allows an influx of calcium in 
larger amounts into the pre-synaptic nerve terminal followed 
subsequently by the release of large amounts of 
neurotransmitters, leading to exaggerated neuromuscular 
activity.  
 
Another mechanism by which hypomagnesemia and 
decreased intracellular magnesium concentration  alters the 
neuromuscular excitability is attributed to the effects of magnesium  
on calcium handling by the muscle cell. 
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DIAGNOSIS OF MAGNESIUM DEFICIENCY 
 
 
 Magnesium deficiency can be assessed primarily by 
determining the serum magnesium concentration and intracellular 
magnesium content. 
Serum Magnesium Concentration 
 
Magnesium is primarily an intracellular cation. Only less 
than 1% of the total body magnesium content is present in the 
extracellular fluid. Hence,  the serum magnesium concentration 
may not reflect the actual intracellular magnesium content. The 
measurement of the concentration of serum magnesium is the most 
commonly used test to assess magnesium status. The serum 
magnesium level less than 1.7 mg/100ml denotes the presence of 
hypomagnesemia. 
 
Exogenous and endogenous catecholamines may cause a 
slight decrease in the serum magnesium concentration.  Increased  
catecholamine leves may contribute to the occurance of 
hypomagnesemia in states of acute illness and stress
17
.  
Hypovolemia and rhabdomyolysis (cellular magnesium release) 
may increase the serum magnesium concentration and may falsely 
mask the intracellular magnesium deficit. 
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Intracellular Magnesium Content 
 
The magnesium level of the peripheral leucocyte has been 
studied, it parallels with the magnesium content of skeletal and 
cardiac muscle. Estimation of the intracellular magnesium content 
appears to be a good marker of total body magnesium level  than 
the  magnesium concentration in the serum. 
 
Magnesium Tolerance Test 
 
It is an accurate method of assessing magnesium status of the 
body.  Parenterally  administered magnesium  is retained at higher 
rate in both hypomagnesemic patients and patients who have 
normal magnesium levels  at risk of developing hypomagnesemia.. 
 
The recommended protocol is as follows: 
 
1. Baseline  urine (spot and timed) should be collected 
for estimating magnesium creatinine ratio.  
2. 0.2 meq (2.4 mg) elemental magnesium per kg body 
weight in 50 ml 5% dextrose water should be infused 
for 4 hours.  
3. 24 hours urine collection to estimate magnesium level. 
4. Percent  of magnesium retained should be calculated 
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using the following formula. 
 
percentage   (Post infusion 24 hours,) – (preinfusion  
magnesium = 1 – urine Mg2+/ Cr) x (post infusion Cr) x 100% 
retained     Total  Mg2+ administered   
 
 
5.  Criteria for  diagnosis: 
>1/2  retention at 1 day = definite deficiency 
 >1/4  retention at 1 day =probable deficiency 
 
Treatment of Magnesium Deficiency 
 
Those who have clinical manifestations suggesting 
hypomagnesemia and are at risk of becoming hypomagnesemic 
must be given magnesium therapy 
Most patients with magnesium deficiency can be treated by g 
dietary advice itself.  But , losses through GIT or kidney is present, 
supplements should be given. Before starting therapy, renal 
function should be assessed. Even in severely hypomagnesemic 
subjects, about 50% of the dose administered is excreted in the 
urine so in the presence of renal failure, therapeutic doses should 
be reduced markedly.  At magnesium levels about 1 to 2 
mequivalents/kg, patients will be symptomatic. 
 
Patients with moderate  to severe magnesium deficiency are 
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usually  symptomatic and should be treated by parenterally 
administering magnesium. 
Administration of Parenteral Magnesium 
 
A single dose of IV Mg
++
 can be effective in the treatment of 
hypomagnesemia and a large amount of the dose administered will 
be excreted by the kidneys. 
 
 The  maximum loading dose of Mg
++  
recommended was 
found to be 150 mg/min
72
. In emergency situations such as 
ventricular tachycardia or ventricular fibrillation, the adult ACLS 
guidelines recommends  1 g of magnesium diluted in 100 ml to be 
given over 1 to 2 minutes
73
. During magnesium therapy,  
continuous electrocardiogram monitoring should be done to avoid 
cardiac toxicity. Blood pressure monitoring should also be done  
during IV administration of Mg
++  
since hypotension may be caused 
if rapidly infused.  The infusion should be given slowly if  
hypotension occurs.  Rapid  IV administration of Mg
++
  may cause 
cutaneous flushing, sweating, fall in blood pressure, somnolence, 
decreased deep tendon reflexes,  hypocalcemia, tetany, respiratory 
impairment  followed by respiratory failure and cardiac arrest can 
occur. 
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These side effects can be reduced by slowing the infusion 
rate. During drug therapy,  serum magnesium level, neurological 
status, respiratory status, and renal function shoud also be 
monitored. Before  starting treatment and also during treatment, 
assessment of patellar reflex should be done. If there is any 
impairment of the reflexes, the therapy should be stopped 
immediately. 
If  renal insufficiency is present, the magnesium dose is 
reduced by 25% to 50% to prevent magnesium overload. 
Magnesium therapy is closely guided according to the serum 
magnesium level to avoid toxicity. Most common complication 
associated with MgSO4 administration is hypocalcemia. The sulfate 
in MgSO4 binds with calcium, forming calcium sulfate and 
reducing ionized calcium. Zaloga and Charnow suggested IV 
magnesium chloride, instead of MgSO4 to prevent  precipitation of 
calcium sulphate. Calcium gluconate should be kept ready for the 
emergency management of hypocalcemia or tetany. 
Administration of Oral Magnesium 
For mild forms of hypomagnesemia, oral magnesium 
supplementation can be given, although its bioavailability may 
vary.  Higher doses of oral magnesium salts may often cause 
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diarrhea. However, Mg
++
 in the Mg
++
 chloride form or in enteric-
coated tablets is well tolerated usually. A course of three 
magnesium chloride tablets per day for 30 days may reduce the 
deficiency in most patients
74
. In patients on diuretics, the 
substitution or addition of a potassium/ magnesium-sparing diuretic 
may prove beneficial. 
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HYPERMAGNESEMIA 
 
 
 
 
Hypermagnesemia usually occurs iatrogenically and is 
commonly observed in cases of acute and chronic renal failure. It is 
especially seen with    administration of exogenous magnesium 
such as antacids, enemas or parenteral nutrition. 
 
In  early stages of chronic renal failure, serum magnesium 
level seems to be normal. As renal insufficiency  worsens, Mg2+ 
loss increases in  parallel with that of  Na2+and other elements. 
Excess Mg2+ can be removed by dialysis, but the use of dialysate 
may itself  cause hypermagnesemia  because of its high magnesium 
concentration. Therapeutic administrationof magnesium 
parenterally conditions like toxemia of pregnancy, adrenal 
insufficiency and hypothyroidism may result in magnesium excess. 
 
 Enemas  rich in magnesium content may cause 
hypermagnesemia even in subjects having functional kidneys. This 
has been attributed to the  ECF depletion which might reduce the 
Mg2+ loss in urine. 
 
 Magnesium excess may manifest clinically if Mg2+ levels 
are more than 4 mequivalents/L. 
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Table 2: Dose related manifestations of hypermagnesemia 
Magnesium Serum 
level (mg/dL) 
Dose related effects 
 
1.7–2.4 Normal serum levels 
5–8 Nausea, headache, light headedness, 
cutaneous flushing. 
9–12 Absent deep tendon reflexes, somnolence, 
hypotension. 
12–15 Sinoatrial and atrioventricular block, muscle 
paralysis, hypoventilation 
>15 Cardiac asystole, respiratory arrest, coma 
  
Neurological manifestations occur when plasma magnesium 
level exceeds 10 meq/L.  Depression of neuromuscular function 
occurs initially which is characterized by impaired / absent DTR. 
paresis of muscles which act voluntarily occur resulting in  flaccid 
quadriparesis/ insufficiency in respiration . Level  of consciousness  
may not be affected. If magnesium is present in excess amounts, 
altered sensorium can occur. 
 
 When serum Mg2+  more than  (15 mequivalent/l), cardiac 
effects occur.  Hypotension,  prolonged  PR-interval in ECG, 
intraventricular conduction defects, complete heart block or cardiac 
77 
 
arrest in systole may occur. 
 
Treatment of magnesium excess are withholding of the  
magnesium infusion, dialysis by PD/HD . Calcium  blocks the 
effects  of Mg2+. Hence, IV administration of calcium ion 5-10 
meq (200 mg) may be required to treat the manifestation of 
hypermagnesemia. 
 
Magnesium  can also be used in the treatment of COPD and  
bronchial asthma. Several studies have reported that there will be 
an improvement in peak expiratory flow rates after infusion of 
magnesium who are not responding to the conventional therapy. 
Magnesium is also used in the treatment of severe preeclampsia 
and eclampsia , as a tocolytic in preterm labour.  Anticonvulsant  
effect may be due to the  depression of neuromuscular transmission 
or as a result of  direct depressant effect on smooth muscle (or) as a 
central nervous system depressant. Tocolytic  effect  of magnesium 
is due to antagonism of calcium mediated myometrial contraction. 
Now magnesium has been on trial for the treatment of vascular 
headaches. 
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MATERIALS AND METHODS 
 
 
 
 
Data resource: 
 
 50 patients diagnosed of having acute myocardial infarction,   
admitted to IMCU, Coimbatore medical college and hospital, over a 
period of 1 year i.e., between August 2013 to August 2014 were 
selected by using simple random method.  
Selection of patients: 
 
Inclusion Criteria: 
 
Patients who presented to the hospital within 12 hours of onset 
of symptoms were included in the study. 
 
The following criteria has been used to diagnose acute 
myocardial infarction. The presence of any of the two criteria has 
been considered : 
1. History of discomfort in the chest. 
 
2. Changes  in the ECG suggestive of acute myocardial infarction  
3. Rise of cardiac enzymes.  
 
Exclusion Criteria 
 
1. Patients having hypokalemia. 
2. Patients on diuretics 
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After the selection of patients through random method, after 
obtaining informed written consent from all the patients included in 
the study, relevant history and physical examination was done. 
Patients were subjected to undergo investigations like complete 
blood count, urine examination, blood sugar, blood urea, serum 
creatinine, fasting lipid profile, cardiac enzymes and ECG was done 
in all cases.  
Estimation  of serum magnesium level was done on day 1 and 
day 5. 
Method of estimation serum magnesium: 
 
The method used was colorimetric end point test with Xylidyl 
blue as the reagent.  
Magnesium standard: 2.5 mg/dL. 
 
 
Principle: 
 
Magnesium  reacts with xylidyl blue at alkaline pH resulting in 
the formation of a chelating red colored compound. The increase in 
the red colour (or) the  decrease in blue color are proportionate to the 
concentration of magnesium in the serum.. 
 
Specimen 
 
Analysis of non-hemolyzed serum or lithium heparin plasma 
80 
 
may be done since the concentration of magnesium inside the red 
cells is 10 times greater than that in the ECF. Separation  of serum 
from the cell should be done as early as possible and hemolysis 
should be avoided. 
 
Normal  range for magnesium 
 
Serum magnesium: 1.6 – 2.4 mg/dl. 
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RESULTS 
 
The data collected was statistically analysed using various 
statistical tools such as ANOVA, Chi-square test, student ‘t’ test. 
 
Table-2: Age and Sex Distribution of the Study group 
 
Age range (years) 
 Sex 
Total 
 
    
Male 
 
Female 
 
    
      
30 – 40 10  -- 10  
      
40 – 50 14  2 16  
      
50 – 60 5  5 10  
      
60 – 70 11  1 12  
      
70 – 80 2  -- 2  
      
 
 
In this study group of 50 cases, 42 were males and 8 were 
female patients with a male-female ratio of 5.25:1. The maximum 
Incidence of acute myocardial infarction was seen in the 4
th
 and 5
th
 
decades, followed by 6
th
 and 7
th
 decades. 28% patients were in the 
age group of 4
th
 and 5
th
 decade, 22% were in the age group of 60-
70. 
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Figure-1: Age and Sex Distribution of the Study group 
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Table-3: Religion wise Distribution of cases 
 
 
Religion No. of cases Percentage 
   
Hindus 39 78.00 
   
Muslims 11 22.00 
   
 
 
In the study of 50 patients, 39 (78%) were Hindus and 11 
(22%) were Muslims. The higher incidence of acute myocardial 
infarction is not factual one but reflects the difference in 
population. 
 
 
Figure-2: Religion wise Distribution of cases 
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Diet: 
 
In the study of 50 patients, 15 (30%) patients were 
vegetarian by diet and 35 (70%) of them consumed mixed diet. 
Non-vegetarian run higher risk of acute myocardial infarction 
owning to their higher content of cholesterol in their diet compared 
to the vegetarian. 
 
 
Figure-3: Diet 
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Table-4: Risk Factors 
 
 
Risk factors No. of cases Percentage 
   
Smoking 35 70.00 
   
Family history of HTN, DM, 
IHD, 10 20.00 
CVA   
   
Obesity 12 24.00 
   
Hypertension 15 30.00 
   
Diabetes mellitus 18 36.00 
   
Dyslipidemia 6 12.00 
   
 
 
Smoking 
 
In the study, smoking is the most common risk factor found 
in the patients with acute myocardial infarction. Cigarette smoking 
accelerates coronary atherosclerosis in both sexes and at all ages 
and increases the risk of thrombosis, plaque instability and 
myocardial infarction. In addition, by increasing myocardial 
oxygen needs and reducing oxygen supply, it aggravates angina. 
 
Obesity 
 
In the present study, out of 50 patients, 12 (24%) were found 
to be obese based on National Cholesterol Education Programme. 
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Waist circumference was measured in all patients. Men  whose 
waist circumference is more than 102 cm and females whose waist 
circumference is more than 88cms were considered to be obese. 
In the present study of 50 patients, 15 (30%) patients were 
found to be hypertensive. Patients whose blood pressure is more 
than 130/85 are considered to be hypertensive. 
 
In the present study of 50 patients,18(36%) patients were 
found to be diabetics and 12 (24%) patients were found to be 
dyslipidemic. 
 
 
Table-5: Time of Presentation 
 
Time at presentation No. of cases Percentage 
   
0 – 3 hours 14 28.00 
   
3 – 6 hours 23 46.00 
   
 
 
In the present study, 23 (46%) cases presented to the hospital 
between 3-6 hours of onset of symptoms and 14 (28%) cases 
presented between 0-3hours. 
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Presentation to the Hospital 
Chest pain was the commonest symptom and was present in all 
of the patients in the present study (100%). In this study chest pain is 
associated with sweating 13 (26%) of patients. Chest pain is 
associated with breathlessness in 8 (16%) of the patients. Palpitation 
associated with chest pain was present in 1 patient (2%). 
Variation in type of Myocardial Infarction 
In the present study of 50 patients, 21 (42%) patients had 
anterior wall MI, 17 (34%) patients had inferior wall MI and 9 (18%) 
patients had anteroseptal MI and 3 (6%) patients had anterolateral 
MI. 
 
Figure-4: Time of Presentation 
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Serum  magnesium level  in  acute  myocardial  infarction  in  
relation  to arrhythmia 
 
In this cross sectional study of 50 patients, the mean serum 
magnesium level on day-1 in all 50 patients was 1.86±0.39 and the 
mean serum magnesium level on day-5 was 2.26±0.5. 
 
Mean serum magnesium level in the group with Arrhythmia on 
Day-1and Day-5 
 
In the present study, out of 50 patients 25 patients had 
significant ventricular  premature  contractions or ventricular  
tachycardia or ventricular fibrillation during their 5-days course in 
the hospital.
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Table-6: Serum magnesium levels in patients with arrhythmias 
 
Serum magnesium 
Day-1 Percent Day-5 Percent 
 
levels (mg/dL) 
 
     
      
<1.6 8 16.00 2 4.00  
      
1.6 to 2.40 17 34.00 16 32.00  
      
>2.4 -- -- 2 4.00  
      
 
 
 
 
Table-7: Serum magnesium levels in patients without 
arrhythmias 
 
Serum magnesium 
Day-1 Percent Day-5 Percent 
 
levels (mg/dL) 
 
     
      
<1.6 2 4.00 -- --  
      
1.6 to 2.40 17 34.00 14 28.00  
      
>2.4 6 12.00 9 18.00  
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Table-8: Mean serum magnesium level 
 
 
 Day-1 Day-5 
   
Mean serum magnesium level 
in 50 cases 1.86±0.39 2.26±0.50 
   
   
Mean serum magnesium level 
in 1.65±0.26 1.98±0.25 
patients with   
arrhythmia(25patients)   
   
Figure-5: Mean serum 
magnesium level 
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Table-9: Comparison of Serum Magnesium level in 
patients with Arrhythimas and without 
Arrhythmias (Day-1) 
 
 
No. of 
Serum    
 
magnesium t- value p-value 
 
 
Cases 
 
 
Day-1 
   
     
Mean serum 
magnesium 25 1.65±0.26    
level in patients with      
arrhythmia   
4.63 <0.001 
 
    
Mean serum 
magnesium 25 2.08±0.41 
 
   
level in patients without     
arrhythmia      
      
 
 
The above table shows that out of 50 patients, 25 patients 
had arrhythmias. The mean value of serum magnesium on day-1 
those with arrhythmias is 1.65±0.26 those without arrhythmias is 
2.05±0.4 (p<0.001). There is a significant difference in the 
magnesium level in patient with arrhythmias and without 
arrhythmias. 
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Figure-6: Comparison of Serum Magnesium 
level in patients with Arrhythimas and without 
Arrhythmias (Day-1) 
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Table-10: Comparison of Serum Magnesium level in patients 
with Arrhythimas and without Arrhythmias (Day-5) 
 
 
No. of 
Serum    
 
magnesium t- value p-value 
 
 
cases 
 
 
Day-5 
   
     
Mean serum 
magnesium 20 1.98±0.25 
4.17 
<0.001 
 
level in patients with    
Arrhythmia    
    
Mean serum 
magnesium 23 2.48±0.52  
level in patients without    
Arrhythmia      
      
 
 
 
 
 
The above table shows that serum magnesium  level in patients 
with arrhythmia on Day-5 is 1.98±0.25 and in those without 
arrhythmia is 2.48±0.5. The difference between these two is found to 
be statistically significant with p- value (p<0.001). 
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Figure-7: Comparison of Serum Magnesium level in 
patients with Arrhythimas and without 
Arrhythmias (Day-5) 
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Mortality: 
 
In the above study of 50 patients, 7 patients died during their 5 
days hospital course. 5 patients were died of ventricular 
tachycardia or ventricular fibrillation, 2 patients were died of 
cardiogenic shock. Mortality percentage was 14%  
 
95 
 
DISCUSSION 
 
 
Magnesium ion has recently been considered as a principle 
cardiovascular cation. It has many critically significant roles in the 
maintenance of normal homeostasis of the body. It plays a major 
role in cardiac homeostasis. Magnesium is essential ATP activation 
necessary for the maintenance of the sodium-potassium pump. 
Magnesium deficiency has been attributed to the causation of 
arrhythmias in acute myocardial infarction patients. 
 
In the study group comprising of 50 patients, 42 were males 
and 8 were females with a male-female ratio of 5.25:1. The 
maximum incidence of acute myocardial infarction was seen in the 
4
th
 and 5
th
 decades. 
 
In the present study of 50 patients, the mean serum 
magnesium level on day-1 in all 50 patients was 1.86±0.39 and the 
mean serum magnesium level on day-5 was 2.26±0.5. 
 
Abraham et al
13
 studied the level of serum  magnesium in 65  
patients admitted and diagnosed to have acute myocardial 
infarction. Concentration of magnesium in serum was noticed to be 
reduced in patients who were diagnosed with AMI (mean 1.70 
mg/dl, p<0.001) or acute coronary insufficiency (mean 1.61 mg/dl, 
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p<0.01), but was not seen in the control group or patients had chest 
pain of non cardiac origin (mean 1.91 mg/dl). 
Singh A et al
75
 investigated magnesium levels in the serum 
of twenty patients diagnosed of having acute myocardial infarction 
on the 1
st
, 7
th
 and 12
th
 day of admission. In most of the cases, there 
was a marked reduction in the magnesium level of the serum on the 
first day. 
 
Dimtruk
76
 conducted the study among 67 patients diagnosed 
with  ischemic heart disease and made out that there was a 
remarkable decrease in the magnesium levels in the serum during 
the first 3 days from the time of presentation and found that the 
magnesium levels returned back to normal by 15-25 days from the 
time of presentation. 
 
Sachdev et al
77
 (1978) selected 30 patients, diagnosed with 
myocardial infarction and monitored the magnesium levels within 
24 hours, 5
th
 and 8
th
 day and it was found to be 1.83±0.087 mgm%, 
1.91±0.149 and 1.97±0.089 whereas in the control group, it was  
2.44±0.162 mgm%. The values were reported to be statistically 
reduced on all the three days and increased thereafter. 
 
In the present study, the serum magnesium level on day-1 
was significant lower in patients with arrhythmias than those 
without arrhythmia (p<0.001). There was an increase in serum 
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magnesium from Day-1 to Day-5 in both those with arrhythmias 
and those without arrhythmias. 
 
Ceremuzynski et al
7 
selected 48 patients with acute 
myocardial infarction of duration over 24 hours and infused  
magnesium or placebo. The occurrence of ventricular tachycardia 
(3 or more subsequent premature ventricular beats with a rate more 
than 120/ min) was significantly decreased (p<0.001), but the 
occurrence of other ventricular arrhythmias was unaffected. 
 
Raismusen et al
21
 selected 273 patients with diagnosis  of 
acute myocardial infarction and subjected them to IV 
administration of magnesium or placebo.  A  significant reduction  
in the occurrence of ventricular arrhythmia in the magnesium 
group was noticed when compared to placebo group (p<0.05). 
 
Shecter et al
79
 subjected 103 patients diagnosed of having 
acute myocardial infarction to magnesium infusion or placebo for 
48 hours.  A  significant fall in mortality rate (p<0.01) was found. 
The occurrence of tachyarrhythmias in need of treatment (10/50) 
has been very low in the magnesium group when compared to the 
placebo group (24/53). 
 
Smith et al
80
 randomly administered   24 hours continuous 
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magnesium sulphate infusion or placebo in 400 patients with the 
suspicion AMI. Out of which, 200 patients were diagnosed of 
having acute myocardial infarction. There is no significant 
variation in the mortality rate or the occurrence of ventricular 
dysrhythmia in need of treatment among the magnesium and 
placebo groups. 
 
Abraham et al
81
 randomly allocated 94 patients diagnosed of 
having acute myocardial infarction and administered a daily bolus 
of magnesium of about 30 mmol or placebo for 3-days. No  
significant variation was noticed in the mortality rate or life 
threatening arrhythmias among patients on magnesium treatment 
and with placebo. 
 
Felstedt et al
82
 randomly subjected 298 patients with the  
suspicion of acute myocardial infarction to  magnesium infusion or 
placebo for 24 hours. Myocardial infarction was confirmed in 162 
patients. During 245 days period, no variation was noted in the 
occurrence of tachyarrhythmias. Increase in the occurrence of 
bradyarrhythmias was noted among patients infused with 
magnesium.  
 
Singh et al
83
 subjected 264 patients with suspicion of acute 
myocardial infarction to potassium, magnesium, 2% glucose or 
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10% glucose infusion. 228 patients were confirmed to have 
myocardial infarction. There was no difference in the mortality rate 
and ventricular tachycardia or fibrillation between the two groups. 
 
Morton et al
84
 assigned 76 patients to get either magnesium 
infusion 0.38 mmol/l per kg every 12
th
 hourly or placebo for the 
first 36 hours of hospital stay. No difference was noticed in the 
occurance of ventricular tachycardia among the two study groups. 
 
Dyckner T et al, among 905 admission, found 342 patients 
with acute myocardial infarction, 563 with other diagnoses. Both  
acute myocardial infarction and non AMI group had markedly 
reduced serum magnesium levels compared to the reference group. 
The occurrence of life threatening ventricular premature beats, 
ventricular tachycardia or ventricular fibrillation on admission was 
found to be high in patients with acute myocardial infarction with 
reduced serum magnesium levels. 
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SUMMARY 
 
This study was carried out in 50 patients of acute myocardial 
infarction who are admitted to the ICCU, Coimbatore Medical 
College Hospital, Coimbatore. 
 
1. The male to female ratio in the study group was 5.25:1 and the 
maximum incidence of acute myocardial infarction was seen in 
4
th
 and 5
th
 decade.  
2. In the study Hindus were 78% and Muslim were 22%.  
3. In the study, the most common presentation symptom was 
chest pain and is associated with sweating in 26% of patients 
and breathlessness in 16% of patients and palpitation in 2%.  
4. In the study, the most common risk factor found was smoking 
followed by hypertension and diabetes.  
5. In the study group, mean serum magnesium level in 50 patients 
on day-1 is 1.86±0.39 and on day-5 is 2.26±0.5.  
6. In the study group, mean serum magnesium level in 25 patients 
with arrhythmia is 1.65±0.26 on day-1 and 1.98±0.25 on day-5.  
7. In the study group, mean serum magnesium level in 25 patients 
without arrhythmia is 2.05±0.41 on day-1 and2.48±0.52 on 
day-5. 
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8. The difference between the magnesium level in patients with 
arrhythmia and without arrhythmia is statistically significant on 
both day-1 and day-5.  
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CONCLUSION 
 
 
 
Coronary artery disease is the major cause of morbidity and 
mortality throughout the world. Major cause of death in coronary 
artery disease may be due to complications like arrhythmias. 
In the present study, patients with acute myocardial infarction 
with low magnesium levels are more prone to develop ventricular 
arrhythmias compared to those who are having normal magnesium 
levels. Magnesium replacement therapy in patients with acute 
myocardial infarction who are having low serum magnesium level 
may reduce the incidence of arrhythmias. 
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PROFORMA 
 
Name: Sl. No. Unit 
Age IP No. DOA 
Sex  DOD  
Occupation Religion  
Final diagnosis   
Presenting Symptoms   
1. Chest pain   
2. Sweating   
3. Dyspnoea   
4. Orthopnea   
5. PND   
6. Palpitation   
7. Others   
History of present 
illness   
1. Chest pain   
 * Location   
 * Nature Severity 
Mild/ moderate/ 
severe 
  Character 
Pricking/ 
throbbing 
   
Squeezing/ 
constricting 
   Burning 
   
Agony/ other 
types 
 
* Onset – Hrs/ days back  
 
* Radiation  
 
* Continuous/ intermittent  
 
* Aggravating factor  
 
* Relieving factor On taking rest/ Drugs 
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2. Sweating     
3. Dyspnea     
 
4. Orthopnea  
 
5. PND  
 
6. Palpitation  
 
* Nature Continuous/ racing of heart beats 
 
Other irregularities 
 
* After excitement/ exercise/ drugs  
 
* Periodicity  
 
* Duration  
 
7. Cough  
 
* Dry/ productive  
 
* Frothy sputum/ hemoptysis  
 
8. Gastrointestinal symptoms  
 
* Nausea  
 
* Vomiting  
 
* Dyspepsia/ heart burn/ indigestion  
 
* Hiccoughs  
 
9. Neurological symptoms:  
 
* Convulsions  
 
* Giddiness/ Fainting  
 
- Time of onset after pain  
 
- Duration  
 
- Consciousness  
 
10. Vascular symptoms  
Phlebitis  
Varicosity Claudicatin  
 
* Raynaud’s phenomenon  
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11. Endocrine symptoms  
 
* Polyuria/ polydypsia/ polyphagia  
 
* Excessive heat/ cold intolerance  
 
* Any change in voice  
 
* Change of hair distribution  
 
12. Miscellaneous  
 
* Swelling of the limbs  
 
* Abdominal distension  
 
* Visual disturbance  
 
III Past History 
 
1. Angina  
 
* Type  
 
* Duration  
 
* Frequency  
 
* Any treatment taken  
 
2. Myocardial infarction  
 
* No. of attacks  
 
* Details of admission and treatment  
 
3. Hypertension  
 
* Duration  
 
* Treatment – not taken/ regular/ irregular  
 
* Controlled/ Uncontrolled  
 
4. Stroke/ TIA  
 
* Treatment  
 
5. Diabetes mellitus  
 
* Duration  
 
* Treatment – Not treated/ regular/ irregular  
 
* Controlled/ Uncontrolled  
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6. Renal diseases  
 
7. Peptic ulcer  
 
8. Rheumatic fever  
 
ii) Diuretics  
 
iii) Others  
 
10. Drinking water source  
 
11. If female  
 
i) Menstrual history  
 
ii) Obstetric history  
 
iii) Oral contraceptives  
 
 
VI} General Physical Examination 
 
1.  Built: Well built/ dwarf/ average 
 
Height __________ Weight __________ 
 
2. Nutrition: Normal/ Obese/ undernourished  
 
3. State of consciousness  
 
4. Cyanosis  
 
5. Clubbing  
 
6. Anemia  
 
7. Edema  
 
8. Xanthoma/ Xanthelasmas  
 
9. Arcus senilis/ Juvenilis  
 
VII] Systemic Examination 
 
1. Pulse  
 
* Rate  
 
* Rhythm  
 
* Character  
 
* Volume  
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* Condition of vessel wall – normal/ thickened  
 
* Other peripheral pulses  
 
2. BP  
 
Upper limb Lower limb 
  
  
3. JVP  
 
4. Epigastric pulsation  
 
a) Inspection  
 
i) Shape of chest  
 
ii) Apical impulse  
 
iii) Other pulsations  
 
b) Palpation  
 
i) Apical impulse  
 
ii) Palpable heart sounds  
 
iii) Parasernal heave  
 
iv) Thrills  
 
v) Other pulsations  
 
c) Percussion  
 
i) Left border of the heart  
 
ii) Right border of the heart  
 
iii) Upper border of liver dullness  
 
iv) Any abnormal areas of dullness (Lt/ Rt I ics)  
 
d) Auscultation:  
 
i) Heart sounds: Normal/ accentuated/ muffled/ slit  
 
* 1
st
 sound  
 
* 2
nd
 sound  
 
* 3
rd
 sound  
 
* 4
th
 sound  
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Mitral area 
 
Tricuspid area 
 
Pulmonary area 
 
Aortic area: 
 
a)  Extra sound: Irregular rhythm/ triple rhythm/ galloop rhythm 
 
Murmur 
 
Pericardial rub 
 
b) Respiratory system 
 
c) Gastrointestinal system  
 
d) Genitourinary system  
 
 
VIII] Investigation 
 
1. Urine Albumin 
 
Sugar 
 
Micro 
 
2. ECG at the time of admission  
 
3. S.magnesium Sodium Potassium SGOT SGPT 
1
st
 day ______ ______ ______ ______ ______ 
5
th
 day ______ ______ ______ ______ ______ 
IX] Course in Hospital     
 
Clinical 
parameters  ECG Management 
 
1
st
 day 
 
2
nd
 day 
 
3
rd
 day 
 
4
th
 day 
 
5
th
 day 
 
6
th
 day 
 
7
th
 day 
 
X] Final remarks and the summary of the case: 
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                                CONSENT FORM  
Mr/Mrs/Ms………………………………………………………….…
….S/W/D of…………………………………………(legal guardian) 
is being asked to be a participant in the research study titled “ SERUM 
MAGNESIUM LEVELS IN ACUTE MYOCARDIAL INFARCTON 
” in  Coimbatore Medical College. He /she satisfies eligibility as per 
the inclusion criteria. You(legal guardian) can ask any question you 
may have before agreeing to participate. 
Research Being Done 
SERUM MAGNESIUM LEVELS IN ACUTE MYOCARDIAL 
INFARCTION  
Purpose of Research 
        SERUM MAGNESIUM LEVELS IN ACUTE 
MYOCARDIAL INFARCTION   
Procedures involved 
.       It includes details like age, sex and about history of the problem 
and associated risk factors as well as clinical examination. 
       Investigations includes complete hemogram, renal function 
tests(blood urea, serum creatinine), Serum magnesium ,ECG  . 
Decline from Participation 
You have the option to decline from  participation in the study  
existing protocol for your condition. 
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Privacy and Confidentiality 
Privacy of individuals will be respected and any information about 
you or provided by you during the study will be kept strictly 
confidential. 
Authorization to publish Results   
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified. 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained 
to me, and  I may ask questions at any time. 
 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(volunteer)   
 
--------------------------------                          -------------------------------- 
Signature of witness                                               Date 
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xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :       
 taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;Jtj; 
Jiwapy; gl;l nkw;gog;g[ gapYk; khzth;; nkw;bfhs;Sk;           
"fLikahd khuilg;gpd; nghJ ,uj;jj;jpd; bkf;dPrpak; ; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ;
mst[[[[" Fwpj;j Ma;tpy; bra;Kiw kw;Wk; midj;J 
tptu';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis 
bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra 
rpe;jida[lDk; fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j 
Ma;tpypUe;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;. 
 
,lk;  :      ifbahg;gk; / nuif 
ehs; : 
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KEY TO MASTER CHART 
 
 
 
 
 
 
CVS............................Cardiovascular system 
 
RS...............................Respiratory system 
 
mm of Hg ...................Millimeter of mercury 
 
BP...............................Blood pressure 
 
Mg
2+
 ...........................Magnesium 
 
Na
+
 .............................Sodium 
 
K
+
 ...............................Potassium 
 
mg/dL.........................Milligram/ deciliter 
 
meq/l ..........................Milliequivalent liter 
 
VPC…………………Ventricular 
   Premature contractions  
 
VT ..............................Ventricular tachycardia 
 
ECG............................Electrocardiogram 
 
CCF ............................Congestive cardiac failure 
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MASTER CHART 
 
         Serum   
 
Sl. 
     
ECG 
      
 
IP No. Age Sex Symptoms Signs BP in mm HG Days 
M
g
2
+
(
m
g
/
d
L
)
 
N
a
(
m
e
q
/
L
)
 
 
K
+
(
m
e
q
/
L
)
 
Complications 
 
No. dignosis  
 
          
 
             
 
1 52369 40 M Chest pain -6hrs BP=130/90 CVS:S1 S2+ Antero 1 1.7 138  4.4 recovered 
 
      Septal MI 5 2.0 136  4.0  
 
2 52584 60 F chest pain-3hrs BP=100/70 Acute 1 1.7 138  5.0 occasional VPCs 
 
    dyspnoea-3hrs CVS:S1 S2+ Anterior 5 2.2 134  4.8 recovered 
 
      MI       
 
3 52869 60 M chest pain-3hrs BP=180/100 CVS :S1S2+ ant. wall 1 2.0 - 141 -  5.2 - Patient died of VT 
 
      MI 5      
 
4 52964 45 M chest pain BP=180/120CVS:S1 S2+ Ant.septal 1 1.1 138  4.4 Occasional VPC 
 
    sweating: 3hrs  MI 5 2.2 136  4.0 recovered 
 
5 53008 56 M chest pain: 1hrs BP=70/50CVS:S1 Inf.wall MI 1 1.55 138 -  4.4 - cardiogenic shock 
 
     S2+HEART SOUNDS  5     expired on 3rd day 
 
     MUFFLED        
 
6 55956 35 M chest pain:-2hrs BP=110/70CVS:S1 S2+ accute 1 2.6 140  4 4.2 Patient recovered 
 
      Antiwall 5 3.3 142    
 
      MI       
 
7 55972 40 M chest pain-4hrs BP=120/80 CVS:S1 S2+ Anti wall 1 1.2 140  4.2 occasional VPCs 
 
      MI 5 1.5 145  3.8 recovered 
 
8 56688 30 M chest pain-7hrs BP=120/80 CVS:S1 S2+ Anti wall 1 1.9 136  3.4 occasional VPCs 
 
    sweating-5hrs  MI 5 2.2 140  3.6 recovered 
 
9 56883 38 M chest pain-1hrs BP=130/90CVS:S1 S2+ Inf.wall MI 1 1.61 140  4.2 occasional VPCs 
 
    sweating-1hrs   5 1.78 145  3.8 recovered 
 
10 56541 40 M chest pain-3hrs BP=130/90CVS:S1 S2+ ant.hat 1 2.1 139  3.8 Recovered 
 
    sweating-3hrs  wall MI 5 2.9 140  3.6  
 
11 56854 62 M chest pain, Breath BP=160/100CVS:S1S2+ Ant septal 1 1.85 140  3.8 occasional VPCs 
 
    lessness.3hrs  MI 5 1.93 145  3.6 recovered 
 
             
 
12 56512 45 M chest pain-4hrs BP=140/90CVS:S1 S2+ Inf.wall MI 1 2.0 140  5.0 Recovered 
 
       5 2.2 142  4.5  
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Sl. 
No. IP No. Age Sex Symptoms Signs BP in mm HG 
ECG 
dignosis Days 
Serum 
K+(me
q/L) Complications 
 
Mg2+(m
g/dL) 
Na 
(meq/L) 
 
 
 
 
 
13 56598 65 M chest pain-4hrs BP=160/100CVS:S1S2+ Inf.wall MI 1 2.4 137 5 Recovered 
 
       5 3.2 135 4.5  
 
14 56749 45 M chest pain-4hrs BP=160/80CVS:S1 S2+ Inf.wall MI 1 2.8 136 4.2 Recovered 
 
       5 3.0 138 4.8  
 
15 56626 53 M chest pain: 6hrs BP=190/110CVS:S1 S2+ Ant.wall 1 2.0 137 5 Recovered 
 
      MI 5 2.01 135 4.5  
 
16 51652 60 F chest pain :8hrs BP=190/110CVS:S1 S2+ Ant.wall 1 2.4 138 4.1 Recovered 
 
      MI 5 3.2 140 3.2  
 
17 61648 69 M chest pain :8hrs BP=200/60CVS:S1 S2+ Ant.wall 1 2.2 134 4.7 Recovered 
 
      MI 5 2.4 136 4.2  
 
18 
57554 
45 F 
chest pain:6hrs 
sweating:6hrs 
BP=70/40CVS :S1 S2 Inf wall MI 
1 
5 
1.70 
1.92 
136 
138 
4.2
4.8 
occasional VPCs 
recovered 
 
 
 
19 57235 50 M chest pain:6hrs BP=130/70CVS:S1 S2+ Ant.wall 1 1.9 138 4.5 occasional VPCs 
 
      MI 5 2.9 136 4.2 recovered 
 
20 57277 70 M chest pain: 4hrs BP=70/40CVS:S1 S2+ Inf wall MI 1 1.2 137 4.0 
Recovered, 
occasional 
 
    sweating:4hrs   5 1.6 138 3.8 VPC 
 
21 57249 65 M chest pain & BP=130/90CVS:S1 S2+ Antero 1 1.5 136 3.8 Died of VT 
 
    breathlessness-  Septal MI 5     
 
    8hrs        
 
22 54675 82 M chest pain -5hrs BP=130/80CVS:S1 S2+ Ant.wall 1 1.4 136 5.8 occasional VPCs 
 
    breathlessness:6hr  MI 5 2.0 138 4.2 recovered 
 
    S        
 
23 52382 67 M chest pain -3hrs BP=150/100CVS:S1 S2+ Inf wall 1 1.9 135 4.9 Recovered 
 
      MI 5 2.3 138 4.3  
 
24 57496 45 M chest pain BP=110/80CVS:S1 S2+ Inf wall MI 1 1.58 136 3.8 Died of VT 
 
    &breathness -1hrs   5     
 
            
 
25 52491 65 F chest pain-6hrs BP=100/70CVS:S1 S2+ non ST  1 2.3 136 3.9 occasional VPCs 
 
      elevation 5 2.5 138 3.6 recovered 
 
      MI      
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26 57682 65 M chest pain BP=80/60CVS:S1 S2+ INf wall 1 1.70 143  3.9 occasional VPCs 
 
    &sweating-8hrs  MI 5 1.86 139  4.2 recovered 
 
27 57703 39 M chest pain BP=140/100CVS:S1 S2+ Ant septal 1 1.85 140  5.0 occasional VPCs 
 
    &sweating-3hrs  MI 5 1.96 138  5.2 recovered 
 
28 51942 70 M chest pain- BP=180/100 CVS :S1S2+ Ant wall 1 2.3 139  4.3 Recovered 
 
    1hrsdyspnoea 1hrs  MI 5 2.5 138  4.0  
 
             
 
29 57696 43 M chest pain BP=110/70CVS:S1 S2+ extansive 1 1.68 139  5.1 occasional VPCs 
 
    sweating:-7hrs  Ant wall 5 1.72 142  4.9 recovered 
 
      MI       
 
30 52711 30 M chest pain.2hrs BP=120/80 CVS:S1 S2+ Inf wall MI 1 1.9 140  3.8 Recovered 
 
       5 2.4 142  3.8  
 
31 57733 58 M chest pain & BP=110/70CVS:S1 S2+ Ant septal 1 1.70 140  4.8 Occasional VPC, 
 
    breathlessness-  MI 5 1.92 143  5.0 recovered 
 
    8hrs         
 
32 51686 65 F chest pain:6hrs BP=140/90CVS:S1 S2+ Ant wall 1 2.6 141  3.4 Recovered 
 
      MI 5 3.0 138  3.2  
 
33 57786 63 M chest pain :4hrs BP=100/60CVS:S1 S2+ Ant septal 1 1.21 139  4.5 Died of VT 
 
      MI 5      
 
34 57852 48 M chest pain :8hrs BP=100/70CVS:S1 S2+ truk post 1 1.75 140  3.8 RBBB recovered 
 
      MI 5 1.76 142  4.0  
 
35 60119 45 M chest pain; 2hrs BP=100/70CVS:S1 S2+ Ant wall 1 2.1 140  3.8 Recovered 
 
      MI 5 2.2 142  3.6  
 
36 58214 52 M chest pain :10hrs BP=90/60CVS:S1 Inf wall MI 1 1.68 141  5.1 occasional VPCs 
 
     S2+,S3+  5 1.82 139  4.8 recovered 
 
37 58374 46 M chest pain -11hrs BP=90/60CVS:S1 Ant wall 1 1.75 135  4.7 LVF recovered 
 
    palpitation-11hrs S2+,S3+ MI 5 1.92 138  5.2  
 
38 50130 50 M chest pain-6hrs BP=140/90CVS:S1 S2+ Inf wall MI 1 2.4 138  4.2 Recovered 
 
       5 3.0 137  4.0  
 
39 59147 65 M chest pain BP=150/100CVS:S1 Ant lat MI 1 1.1 - 137  4.5 Cardiogenic shock, 
 
    sweating &mi 2hrs S2+,S3+,RS BASAL  5     expires on 2nd day 
 
     CREPITATIONS+        
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40 59268 62 M chest pain-5hrs BP=140/90CVS:S1 S2+ Inf wall MI 1 2.07 132  3.5 recovered 
 
       5 2.04 140  5.0  
 
41 58938 56 F chest pain-4hrs BP=130/80CVS:S1 S2+ Inf wall MI 1 1.7 137  5 occasional VPCs 
 
       5 1.92 142  3.5 recovered 
 
42 61984 85 M chest pain BP=200/120CVS:S1 S2+ Inf wall MI 1 1.64 140  4.2 VT expired on 2nd day 
 
    breathlessness:-   5      
 
    6hrs         
 
43 54917 50 M chest pain -3hrs BP=120/80 CVS:S1 S2+ Ant wall 1 2.5 132  4.2 Recovered 
 
      MI 5 3.0 138  4.0  
 
44 59079 45 F chest pain BP=130/80CVS:S1 S2+ Antero 1 1.70 137  5.1 Recovered 
 
    sweating:-7hrs  Septal MI 5 1.86 135  5.2  
 
45 59729 39 M chest pain -3hrs BP=140/70CVS:S1 S2+ Ant wall 1 1.81 142  4.0 Recovered 
 
      MI 5 1.82 140  3.9  
 
46 59943 49 M chest pain BP=110/70CVS:S1 S2+ Antero 1 1.70 135  3.8 Recovered, occasional 
 
    sweating;-4hrs  Septal MI 5 1.89 140  3.3 VPC 
 
47 70291 40 M chest pain:6hrs BP=110/70CVS:S1 S2+ Ant wall 1 2.8 138  4.0 Recovered 
 
      MI 5 3.2 136  3.8  
 
48 60423 35 M chest pain BP=110/90CVS:S1 S2+ Antero 1 1.67 140  3.5 occasional VPCs 
 
    sweating:6hrs  Septal MI 5 2.35 135  4.0 recovered 
 
49 60089 42 M chest pain :4hrs BP=190/110CVS:S1 S2+ INf wall 1 1.7 142  3.9 Recovered 
 
      MI 5 1.92 140  4.2  
 
50 54917 50 M chest pain:8hrs BP=120/80 CVS:S1 S2+ Ant wall 1 1.5 137  4.2 occasional VPCs 
 
      MI 5 2.3 138  4.0 recovered 
 
 
